Sitagliptin - DrugBank

ID Pharmacology Interactions References Trials Economics Properties Spectra Taxonomy

Targets (1)Enzymes (2)Transporters (1)

Targets (1)Enzymes (2)Transporters (1)Biointeractions (4)

Identification

Name

Sitagliptin

Accession Number

DB01261 (DB07214)

Type

Small Molecule

Groups

Approved, Investigational

Description

Sitagliptin is a new oral hypoglycemic (anti-diabetic drug) of the new dipeptidyl peptidase-4 (DPP-4) inhibitor class of drugs. This enzyme-inhibiting drug is to be used either alone or in combination with metformin or a thiazolidinedione for control of type 2 diabetes mellitus. The drug works to competitively inhibit a protein/enzyme, dipeptidyl peptidase 4 (DPP-4), that results in an increased amount of active incretins (GLP-1 and GIP), reduced amount of release of glucagon (diminishes its release) and increased release of insulin.

Structure

MOL SDF 3D-SDF PDB SMILES InChI View 3D Structure

Synonyms

(2R)-4-OXO-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine

MK-0431

Sitagliptan

Sitagliptin phosphate

Sitagliptina

Sitagliptine

Sitagliptinum

External IDs

LEZ-763 / LEZ763 / MK-0431

Product Ingredients

Not Available

Product Images

Approved Prescription Products

Name	Dosage	Strength	Route	Labeller	Marketing Start	Marketing End
Januvia	Tablet, film coated	100 mg/1	Oral	Lake Erie Medical &Surgical Supply Dba Quality Care Products Llc	2012-03-09	Not applicable	US
Januvia	Tablet, film coated	100 mg	Oral	Merck Sharp & Dohme Limited	2007-03-21	Not applicable	EU
Januvia	Tablet	50 mg	Oral	Merck Ltd.	2012-09-17	Not applicable	Canada
Januvia	Tablet, film coated	50 mg	Oral	Merck Sharp & Dohme Limited	2007-03-21	Not applicable	EU
Januvia	Tablet, film coated	100 mg/1	Oral	Cardinal Health	2006-10-16	Not applicable	US
Januvia	Tablet, film coated	50 mg	Oral	Merck Sharp & Dohme Limited	2007-03-21	Not applicable	EU
Januvia	Tablet, film coated	25 mg	Oral	Merck Sharp & Dohme Limited	2007-03-21	Not applicable	EU
Januvia	Tablet, film coated	50 mg	Oral	Merck Sharp & Dohme Limited	2007-03-21	Not applicable	EU
Januvia	Tablet, film coated	100 mg	Oral	Merck Sharp & Dohme Limited	2007-03-21	Not applicable	EU
Januvia	Tablet, film coated	50 mg/1	Oral	Physicians Total Care, Inc.	2009-05-06	Not applicable	US
Januvia	Tablet, film coated	25 mg	Oral	Merck Sharp & Dohme Limited	2007-03-21	Not applicable	EU
Januvia	Tablet, film coated	100 mg	Oral	Merck Sharp & Dohme Limited	2007-03-21	Not applicable	EU
Januvia	Tablet	25 mg	Oral	Merck Ltd.	2012-09-17	Not applicable	Canada
Januvia	Tablet, film coated	50 mg/1	Oral	Merck Sharp & Dohme Limited	2006-10-16	Not applicable	US
Januvia	Tablet, film coated	50 mg/1	Oral	Cardinal Health	2006-10-16	Not applicable	US
Januvia	Tablet, film coated	25 mg	Oral	Merck Sharp & Dohme Limited	2007-03-21	Not applicable	EU
Januvia	Tablet, film coated	100 mg	Oral	Merck Sharp & Dohme Limited	2007-03-21	Not applicable	EU
Januvia	Tablet, film coated	25 mg/1	Oral	Avera Mc Kennan Hospital	2016-10-20	Not applicable	US
Januvia	Tablet, film coated	100 mg/1	Oral	Remedy Repack	2014-03-03	2017-06-20	US
Januvia	Tablet, film coated	25 mg	Oral	Merck Sharp & Dohme Limited	2007-03-21	Not applicable	EU
Januvia	Tablet, film coated	100 mg	Oral	Merck Sharp & Dohme Limited	2007-03-21	Not applicable	EU
Januvia	Tablet, film coated	50 mg/1	Oral	Cardinal Health	2006-10-16	Not applicable	US
Januvia	Tablet, film coated	100 mg/1	Oral	A S Medication Solutions	2006-10-16	2017-06-20	US
Januvia	Tablet, film coated	50 mg	Oral	Merck Sharp & Dohme Limited	2007-03-21	Not applicable	EU
Januvia	Tablet, film coated	50 mg	Oral	Merck Sharp & Dohme Limited	2007-03-21	Not applicable	EU
Januvia	Tablet, film coated	25 mg/1	Oral	Merck Sharp & Dohme Limited	2006-10-16	Not applicable	US
Januvia	Tablet, film coated	50 mg/1	Oral	Cardinal Health	2006-10-16	2017-04-27	US
Januvia	Tablet, film coated	25 mg	Oral	Merck Sharp & Dohme Limited	2007-03-21	Not applicable	EU
Januvia	Tablet, film coated	100 mg	Oral	Merck Sharp & Dohme Limited	2007-03-21	Not applicable	EU
Januvia	Tablet, film coated	100 mg/1	Oral	Cardinal Health	2006-10-16	Not applicable	US
Januvia	Tablet, film coated	50 mg	Oral	Merck Sharp & Dohme Limited	2007-03-21	Not applicable	EU
Januvia	Tablet, film coated	25 mg	Oral	Merck Sharp & Dohme Limited	2007-03-21	Not applicable	EU
Januvia	Tablet, film coated	50 mg/1	Oral	Avera Mc Kennan Hospital	2016-01-11	Not applicable	US
Januvia	Tablet, film coated	100 mg/1	Oral	Physicians Total Care, Inc.	2007-12-13	Not applicable	US
Januvia	Tablet, film coated	25 mg	Oral	Merck Sharp & Dohme Limited	2007-03-21	Not applicable	EU
Januvia	Tablet, film coated	100 mg	Oral	Merck Sharp & Dohme Limited	2007-03-21	Not applicable	EU
Januvia	Tablet	100 mg	Oral	Merck Ltd.	2008-01-02	Not applicable	Canada
Januvia	Tablet, film coated	100 mg/1	Oral	A S Medication Solutions	2006-10-16	2017-06-20	US
Januvia	Tablet, film coated	50 mg	Oral	Merck Sharp & Dohme Limited	2007-03-21	Not applicable	EU
Januvia	Tablet, film coated	50 mg	Oral	Merck Sharp & Dohme Limited	2007-03-21	Not applicable	EU
Januvia	Tablet, film coated	100 mg	Oral	Merck Sharp & Dohme Limited	2007-03-21	Not applicable	EU
Januvia	Tablet, film coated	100 mg/1	Oral	Merck Sharp & Dohme Limited	2006-10-16	Not applicable	US
Januvia	Tablet, film coated	100 mg/1	Oral	Cardinal Health	2006-10-16	2017-04-27	US
Januvia	Tablet, film coated	25 mg	Oral	Merck Sharp & Dohme Limited	2007-03-21	Not applicable	EU
Ristaben	Tablet, film coated	50 mg	Oral	Merck Sharp & Dohme Limited	2010-03-15	Not applicable	EU
Ristaben	Tablet, film coated	100 mg	Oral	Merck Sharp & Dohme Limited	2010-03-15	Not applicable	EU
Ristaben	Tablet, film coated	50 mg	Oral	Merck Sharp & Dohme Limited	2010-03-15	Not applicable	EU
Ristaben	Tablet, film coated	25 mg	Oral	Merck Sharp & Dohme Limited	2010-03-15	Not applicable	EU
Ristaben	Tablet, film coated	25 mg	Oral	Merck Sharp & Dohme Limited	2010-03-15	Not applicable	EU
Ristaben	Tablet, film coated	100 mg	Oral	Merck Sharp & Dohme Limited	2010-03-15	Not applicable	EU
Ristaben	Tablet, film coated	50 mg	Oral	Merck Sharp & Dohme Limited	2010-03-15	Not applicable	EU
Ristaben	Tablet, film coated	100 mg	Oral	Merck Sharp & Dohme Limited	2010-03-15	Not applicable	EU
Ristaben	Tablet, film coated	25 mg	Oral	Merck Sharp & Dohme Limited	2010-03-15	Not applicable	EU
Ristaben	Tablet, film coated	100 mg	Oral	Merck Sharp & Dohme Limited	2010-03-15	Not applicable	EU
Ristaben	Tablet, film coated	25 mg	Oral	Merck Sharp & Dohme Limited	2010-03-15	Not applicable	EU
Ristaben	Tablet, film coated	100 mg	Oral	Merck Sharp & Dohme Limited	2010-03-15	Not applicable	EU
Ristaben	Tablet, film coated	50 mg	Oral	Merck Sharp & Dohme Limited	2010-03-15	Not applicable	EU
Ristaben	Tablet, film coated	50 mg	Oral	Merck Sharp & Dohme Limited	2010-03-15	Not applicable	EU
Ristaben	Tablet, film coated	25 mg	Oral	Merck Sharp & Dohme Limited	2010-03-15	Not applicable	EU
Ristaben	Tablet, film coated	100 mg	Oral	Merck Sharp & Dohme Limited	2010-03-15	Not applicable	EU
Ristaben	Tablet, film coated	50 mg	Oral	Merck Sharp & Dohme Limited	2010-03-15	Not applicable	EU
Ristaben	Tablet, film coated	25 mg	Oral	Merck Sharp & Dohme Limited	2010-03-15	Not applicable	EU
Ristaben	Tablet, film coated	25 mg	Oral	Merck Sharp & Dohme Limited	2010-03-15	Not applicable	EU
Ristaben	Tablet, film coated	100 mg	Oral	Merck Sharp & Dohme Limited	2010-03-15	Not applicable	EU
Ristaben	Tablet, film coated	50 mg	Oral	Merck Sharp & Dohme Limited	2010-03-15	Not applicable	EU
Ristaben	Tablet, film coated	50 mg	Oral	Merck Sharp & Dohme Limited	2010-03-15	Not applicable	EU
Ristaben	Tablet, film coated	25 mg	Oral	Merck Sharp & Dohme Limited	2010-03-15	Not applicable	EU
Ristaben	Tablet, film coated	100 mg	Oral	Merck Sharp & Dohme Limited	2010-03-15	Not applicable	EU
Tesavel	Tablet, film coated	50 mg	Oral	Merck Sharp & Dohme Limited	2008-01-10	Not applicable	EU
Tesavel	Tablet, film coated	100 mg	Oral	Merck Sharp & Dohme Limited	2008-01-10	Not applicable	EU
Tesavel	Tablet, film coated	50 mg	Oral	Merck Sharp & Dohme Limited	2008-01-10	Not applicable	EU
Tesavel	Tablet, film coated	25 mg	Oral	Merck Sharp & Dohme Limited	2008-01-10	Not applicable	EU
Tesavel	Tablet, film coated	50 mg	Oral	Merck Sharp & Dohme Limited	2008-01-10	Not applicable	EU
Tesavel	Tablet, film coated	100 mg	Oral	Merck Sharp & Dohme Limited	2008-01-10	Not applicable	EU
Tesavel	Tablet, film coated	25 mg	Oral	Merck Sharp & Dohme Limited	2008-01-10	Not applicable	EU
Tesavel	Tablet, film coated	100 mg	Oral	Merck Sharp & Dohme Limited	2008-01-10	Not applicable	EU
Tesavel	Tablet, film coated	25 mg	Oral	Merck Sharp & Dohme Limited	2008-01-10	Not applicable	EU
Tesavel	Tablet, film coated	100 mg	Oral	Merck Sharp & Dohme Limited	2008-01-10	Not applicable	EU
Tesavel	Tablet, film coated	25 mg	Oral	Merck Sharp & Dohme Limited	2008-01-10	Not applicable	EU
Tesavel	Tablet, film coated	100 mg	Oral	Merck Sharp & Dohme Limited	2008-01-10	Not applicable	EU
Tesavel	Tablet, film coated	50 mg	Oral	Merck Sharp & Dohme Limited	2008-01-10	Not applicable	EU
Tesavel	Tablet, film coated	50 mg	Oral	Merck Sharp & Dohme Limited	2008-01-10	Not applicable	EU
Tesavel	Tablet, film coated	25 mg	Oral	Merck Sharp & Dohme Limited	2008-01-10	Not applicable	EU
Tesavel	Tablet, film coated	100 mg	Oral	Merck Sharp & Dohme Limited	2008-01-10	Not applicable	EU
Tesavel	Tablet, film coated	50 mg	Oral	Merck Sharp & Dohme Limited	2008-01-10	Not applicable	EU
Tesavel	Tablet, film coated	25 mg	Oral	Merck Sharp & Dohme Limited	2008-01-10	Not applicable	EU
Tesavel	Tablet, film coated	25 mg	Oral	Merck Sharp & Dohme Limited	2008-01-10	Not applicable	EU
Tesavel	Tablet, film coated	100 mg	Oral	Merck Sharp & Dohme Limited	2008-01-10	Not applicable	EU
Tesavel	Tablet, film coated	50 mg	Oral	Merck Sharp & Dohme Limited	2008-01-10	Not applicable	EU
Tesavel	Tablet, film coated	50 mg	Oral	Merck Sharp & Dohme Limited	2008-01-10	Not applicable	EU
Tesavel	Tablet, film coated	25 mg	Oral	Merck Sharp & Dohme Limited	2008-01-10	Not applicable	EU
Tesavel	Tablet, film coated	100 mg	Oral	Merck Sharp & Dohme Limited	2008-01-10	Not applicable	EU
Xelevia	Tablet, film coated	50 mg	Oral	Merck Sharp & Dohme Limited	2007-03-21	Not applicable	EU
Xelevia	Tablet, film coated	100 mg	Oral	Merck Sharp & Dohme Limited	2007-03-21	Not applicable	EU
Xelevia	Tablet, film coated	50 mg	Oral	Merck Sharp & Dohme Limited	2007-03-21	Not applicable	EU
Xelevia	Tablet, film coated	25 mg	Oral	Merck Sharp & Dohme Limited	2007-03-21	Not applicable	EU
Xelevia	Tablet, film coated	50 mg	Oral	Merck Sharp & Dohme Limited	2007-03-21	Not applicable	EU
Xelevia	Tablet, film coated	100 mg	Oral	Merck Sharp & Dohme Limited	2007-03-21	Not applicable	EU
Xelevia	Tablet, film coated	25 mg	Oral	Merck Sharp & Dohme Limited	2007-03-21	Not applicable	EU
Xelevia	Tablet, film coated	100 mg	Oral	Merck Sharp & Dohme Limited	2007-03-21	Not applicable	EU
Xelevia	Tablet, film coated	25 mg	Oral	Merck Sharp & Dohme Limited	2007-03-21	Not applicable	EU
Xelevia	Tablet, film coated	100 mg	Oral	Merck Sharp & Dohme Limited	2007-03-21	Not applicable	EU
Xelevia	Tablet, film coated	25 mg	Oral	Merck Sharp & Dohme Limited	2007-03-21	Not applicable	EU
Xelevia	Tablet, film coated	100 mg	Oral	Merck Sharp & Dohme Limited	2007-03-21	Not applicable	EU
Xelevia	Tablet, film coated	50 mg	Oral	Merck Sharp & Dohme Limited	2007-03-21	Not applicable	EU
Xelevia	Tablet, film coated	50 mg	Oral	Merck Sharp & Dohme Limited	2007-03-21	Not applicable	EU
Xelevia	Tablet, film coated	100 mg	Oral	Merck Sharp & Dohme Limited	2007-03-21	Not applicable	EU
Xelevia	Tablet, film coated	25 mg	Oral	Merck Sharp & Dohme Limited	2007-03-21	Not applicable	EU
Xelevia	Tablet, film coated	50 mg	Oral	Merck Sharp & Dohme Limited	2007-03-21	Not applicable	EU
Xelevia	Tablet, film coated	25 mg	Oral	Merck Sharp & Dohme Limited	2007-03-21	Not applicable	EU
Xelevia	Tablet, film coated	50 mg	Oral	Merck Sharp & Dohme Limited	2007-03-21	Not applicable	EU
Xelevia	Tablet, film coated	50 mg	Oral	Merck Sharp & Dohme Limited	2007-03-21	Not applicable	EU
Xelevia	Tablet, film coated	25 mg	Oral	Merck Sharp & Dohme Limited	2007-03-21	Not applicable	EU
Xelevia	Tablet, film coated	100 mg	Oral	Merck Sharp & Dohme Limited	2007-03-21	Not applicable	EU
Xelevia	Tablet, film coated	25 mg	Oral	Merck Sharp & Dohme Limited	2007-03-21	Not applicable	EU
Xelevia	Tablet, film coated	100 mg	Oral	Merck Sharp & Dohme Limited	2007-03-21	Not applicable	EU

Approved Generic Prescription Products

Name	Dosage	Strength	Route	Labeller	Marketing Start	Marketing End
Januvia	Tablet, film coated	100 mg/1	Oral	Clinical Solutions Wholsesale	2006-10-16	2017-06-24	US

Approved Over the Counter Products

Not Available

Unapproved/Other Products

Not Available

International Brands

Name	Company
Xelevia	Not Available

Brand mixtures

Name	Labeller	Ingredients
Janumet	Lake Erie Medical &Surgical Supply Dba Quality Care Products Llc	Metformin Sitagliptin
Janumet XR	Merck Sharp & Dohme Limited	Metformin Sitagliptin
Velmetia	Merck Sharp & Dohme Limited	Metformin Sitagliptin

Categories

UNII

QFP0P1DV7Z

CAS number

486460-32-6

Weight

Average: 407.3136
Monoisotopic: 407.118079357

Chemical Formula

C₁₆H₁₅F₆N₅O

InChI Key

MFFMDFFZMYYVKS-SECBINFHSA-N

InChI

InChI=1S/C16H15F6N5O/c17-10-6-12(19)11(18)4-8(10)3-9(23)5-14(28)26-1-2-27-13(7-26)24-25-15(27)16(20,21)22/h4,6,9H,1-3,5,7,23H2/t9-/m1/s1

IUPAC Name

(3R)-3-amino-1-[3-(trifluoromethyl)-5H,6H,7H,8H-[1,2,4]triazolo[4,3-a]pyrazin-7-yl]-4-(2,4,5-trifluorophenyl)butan-1-one

SMILES

N[C@@H](CC(=O)N1CCN2C(C1)=NN=C2C(F)(F)F)CC1=CC(F)=C(F)C=C1F

Pharmacology

Indication

For use as an adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus. Also for use in patients with type 2 diabetes mellitus to improve glycemic control in combination with metformin or a PPARγ agonist (e.g., thiazolidinediones) when the single agent alone, with diet and exercise, does not provide adequate glycemic control.

Structured Indications

Type 2 Diabetes Mellitus

Pharmacodynamics

Sitagliptin is an orally-active member of the new dipeptidyl peptidase-4 (DPP-4) inhibitor class of drugs. The benefit of this medicine is expected to be its lower side-effects of hypoglycemia in the control of blood glucose values. The drug works to diminish the effects of a protein/enzyme (by the inhibition of this protein/enzyme) on the pancreas at the level of release of glucagon (diminishes its release) and at the level of insulin (increases its synthesis and release) until blood glucose levels are restored toward normal, in which case the protein/enzyme-enzyme inhibitor becomes less effective and the amounts of insulin released diminishes thus diminishing the "overshoot" of hypoglycemia seen in other oral hypoglycemic agents.

Mechanism of action

Sitagliptin is a highly selective DPP-4 inhibitor, which is believed to exert its actions in patients with type 2 diabetes by slowing the inactivation of incretin hormones, thereby increasing the concentration and prolonging the action of these hormones. Incretin hormones, including glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), are released by the intestine throughout the day, and levels are increased in response to a meal. These hormones are rapidly inactivated by the enzyme, DPP-4. The incretins are part of an endogenous system involved in the physiologic regulation of glucose homeostasis. When blood glucose concentrations are normal or elevated, GLP-1 and GIP increase insulin synthesis and release from pancreatic beta cells by intracellular signaling pathways involving cyclic AMP. GLP-1 also lowers glucagon secretion from pancreatic alpha cells, leading to reduced hepatic glucose production. By increasing and prolonging active incretin levels, sitagliptin increases insulin release and decreases glucagon levels in the circulation in a glucose-dependent manner. These changes lead to a decrease in hemoglobin A1c (HbA1c)levels, as well as a lower fasting and postprandial glucose concentration. Sitagliptin demonstrates selectivity for DPP-4 and does not inhibit DPP-8 or DPP-9 activity in vitro at concentrations approximating those from therapeutic doses.

Target	Kind	Pharmacological action	Actions	Organism	UniProt ID
Dipeptidyl peptidase 4	Protein	yes	inhibitor	Human	P27487	details

Absorption

Rapidly absorbed following oral administration, with an absolute bioavailability of 87%.

Volume of distribution

198 L [healthy subjects]

Protein binding

The fraction of sitagliptin reversibly bound to plasma proteins is low (38%).

Metabolism

Sitagliptin does not undergo extensive metabolism. In vitro studies indicate that the primary enzyme responsible for the limited metabolism of sitagliptin was CYP3A4 (oxidation), with contribution from CYP2C8.

Route of elimination

Approximately 79% of sitagliptin is excreted unchanged in the urine with metabolism being a minor pathway of elimination. Following administration of an oral [14C]sitagliptin dose to healthy subjects, approximately 100% of the administered radioactivity was eliminated in feces (13%) or urine (87%) within one week of dosing. Elimination of sitagliptin occurs primarily via renal excretion and involves active tubular secretion.

Half life

12.4 hours

Clearance

renal cl=350 mL/min [Healthy subjects receiving 100 mg oral dose]

Toxicity

Not Available

Affected organisms

Humans and other mammals

Pathways

Not Available

Pharmacogenomic Effects/ADRs

Not Available

Interactions

Drug Interactions

Drug	Interaction	Drug group
7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline	7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE may increase the hypoglycemic activities of Sitagliptin.	Experimental
Abacavir	The serum concentration of Abacavir can be decreased when it is combined with Sitagliptin.	Approved, Investigational
Abiraterone	The serum concentration of Sitagliptin can be increased when it is combined with Abiraterone.	Approved
Acetaminophen	The serum concentration of Sitagliptin can be increased when it is combined with Acetaminophen.	Approved
Acetohexamide	Sitagliptin may increase the hypoglycemic activities of Acetohexamide.	Withdrawn
Acetylsalicylic acid	Acetylsalicylic acid may increase the hypoglycemic activities of Sitagliptin.	Approved, Vet Approved
Afatinib	The serum concentration of Sitagliptin can be increased when it is combined with Afatinib.	Approved
Albendazole	The serum concentration of Sitagliptin can be increased when it is combined with Albendazole.	Approved, Vet Approved
Aldosterone	The serum concentration of Sitagliptin can be decreased when it is combined with Aldosterone.	Experimental
Alectinib	The serum concentration of Sitagliptin can be increased when it is combined with Alectinib.	Approved
Alfentanil	The serum concentration of Sitagliptin can be increased when it is combined with Alfentanil.	Approved, Illicit
Alfuzosin	The serum concentration of Alfuzosin can be increased when it is combined with Sitagliptin.	Approved, Investigational
Alprazolam	The serum concentration of Alprazolam can be increased when it is combined with Sitagliptin.	Approved, Illicit, Investigational
Amantadine	The serum concentration of Sitagliptin can be increased when it is combined with Amantadine.	Approved
Ambroxol acefyllinate	The serum concentration of Ambroxol acefyllinate can be decreased when it is combined with Sitagliptin.	Experimental
Amineptine	The serum concentration of Amineptine can be increased when it is combined with Sitagliptin.	Illicit, Withdrawn
Aminohippuric acid	The serum concentration of Sitagliptin can be increased when it is combined with Aminohippuric acid.	Approved
Aminophylline	The serum concentration of Aminophylline can be decreased when it is combined with Sitagliptin.	Approved
Aminosalicylic Acid	Aminosalicylic Acid may increase the hypoglycemic activities of Sitagliptin.	Approved
Amiodarone	The metabolism of Sitagliptin can be decreased when combined with Amiodarone.	Approved, Investigational
Amitriptyline	The serum concentration of Amitriptyline can be increased when it is combined with Sitagliptin.	Approved
Amlodipine	The serum concentration of Sitagliptin can be increased when it is combined with Amlodipine.	Approved
Amprenavir	The serum concentration of Sitagliptin can be decreased when it is combined with Amprenavir.	Approved
Amsacrine	The serum concentration of Sitagliptin can be increased when it is combined with Amsacrine.	Approved
Aprepitant	The serum concentration of Sitagliptin can be increased when it is combined with Aprepitant.	Approved, Investigational
Aripiprazole	The therapeutic efficacy of Sitagliptin can be decreased when used in combination with Aripiprazole.	Approved, Investigational
Arsenic trioxide	The therapeutic efficacy of Sitagliptin can be decreased when used in combination with Arsenic trioxide.	Approved, Investigational
Articaine	The therapeutic efficacy of Sitagliptin can be decreased when used in combination with Articaine.	Approved
Asenapine	The therapeutic efficacy of Sitagliptin can be decreased when used in combination with Asenapine.	Approved
Astemizole	The serum concentration of Sitagliptin can be increased when it is combined with Astemizole.	Approved, Withdrawn
Atazanavir	The metabolism of Sitagliptin can be decreased when combined with Atazanavir.	Approved, Investigational
Atenolol	The serum concentration of Sitagliptin can be increased when it is combined with Atenolol.	Approved
Atomoxetine	The metabolism of Sitagliptin can be decreased when combined with Atomoxetine.	Approved
Atorvastatin	The serum concentration of Atorvastatin can be increased when it is combined with Sitagliptin.	Approved
Azelastine	The serum concentration of Sitagliptin can be increased when it is combined with Azelastine.	Approved
Azithromycin	The serum concentration of Sitagliptin can be increased when it is combined with Azithromycin.	Approved
Balsalazide	Balsalazide may increase the hypoglycemic activities of Sitagliptin.	Approved, Investigational
Benazepril	The risk or severity of adverse effects can be increased when Sitagliptin is combined with Benazepril.	Approved, Investigational
Bendroflumethiazide	The therapeutic efficacy of Sitagliptin can be decreased when used in combination with Bendroflumethiazide.	Approved
Benmoxin	Benmoxin may increase the hypoglycemic activities of Sitagliptin.	Withdrawn
Benzocaine	The serum concentration of Sitagliptin can be increased when it is combined with Benzocaine.	Approved
Bepridil	The serum concentration of Sitagliptin can be increased when it is combined with Bepridil.	Approved, Withdrawn
Betamethasone	The therapeutic efficacy of Sitagliptin can be decreased when used in combination with Betamethasone.	Approved, Vet Approved
Bexarotene	The serum concentration of Sitagliptin can be decreased when it is combined with Bexarotene.	Approved, Investigational
Biperiden	The serum concentration of Sitagliptin can be increased when it is combined with Biperiden.	Approved
Boceprevir	The serum concentration of Sitagliptin can be decreased when it is combined with Boceprevir.	Approved, Investigational
Bortezomib	The metabolism of Sitagliptin can be decreased when combined with Bortezomib.	Approved, Investigational
Bosentan	The serum concentration of Sitagliptin can be decreased when it is combined with Bosentan.	Approved, Investigational
Bosutinib	The serum concentration of Sitagliptin can be increased when it is combined with Bosutinib.	Approved
Brexpiprazole	The therapeutic efficacy of Sitagliptin can be decreased when used in combination with Brexpiprazole.	Approved
Bromocriptine	The serum concentration of Bromocriptine can be increased when it is combined with Sitagliptin.	Approved, Investigational
Bumetanide	The therapeutic efficacy of Sitagliptin can be decreased when used in combination with Bumetanide.	Approved
Buprenorphine	The serum concentration of Sitagliptin can be increased when it is combined with Buprenorphine.	Approved, Illicit, Investigational, Vet Approved
Buserelin	The therapeutic efficacy of Sitagliptin can be decreased when used in combination with Buserelin.	Approved
Buspirone	The serum concentration of Sitagliptin can be increased when it is combined with Buspirone.	Approved, Investigational
Cabazitaxel	The serum concentration of Sitagliptin can be increased when it is combined with Cabazitaxel.	Approved
Cabergoline	The serum concentration of Cabergoline can be increased when it is combined with Sitagliptin.	Approved
Caffeine	The serum concentration of Sitagliptin can be increased when it is combined with Caffeine.	Approved
Canagliflozin	The serum concentration of Sitagliptin can be increased when it is combined with Canagliflozin.	Approved
Candesartan	The serum concentration of Sitagliptin can be increased when it is combined with Candesartan.	Approved
Candoxatril	The risk or severity of adverse effects can be increased when Sitagliptin is combined with Candoxatril.	Experimental
Captopril	The serum concentration of Sitagliptin can be increased when it is combined with Captopril.	Approved
Carbamazepine	The metabolism of Sitagliptin can be increased when combined with Carbamazepine.	Approved, Investigational
Caroxazone	Caroxazone may increase the hypoglycemic activities of Sitagliptin.	Withdrawn
Carvedilol	The serum concentration of Sitagliptin can be increased when it is combined with Carvedilol.	Approved, Investigational
Caspofungin	The serum concentration of Sitagliptin can be increased when it is combined with Caspofungin.	Approved
Celecoxib	The metabolism of Sitagliptin can be decreased when combined with Celecoxib.	Approved, Investigational
Ceritinib	The serum concentration of Sitagliptin can be increased when it is combined with Ceritinib.	Approved
Chloroquine	The serum concentration of Sitagliptin can be increased when it is combined with Chloroquine.	Approved, Vet Approved
Chlorothiazide	The therapeutic efficacy of Sitagliptin can be decreased when used in combination with Chlorothiazide.	Approved, Vet Approved
Chlorotrianisene	The serum concentration of Chlorotrianisene can be decreased when it is combined with Sitagliptin.	Withdrawn
Chlorpromazine	The serum concentration of Sitagliptin can be increased when it is combined with Chlorpromazine.	Approved, Vet Approved
Chlorpropamide	Sitagliptin may increase the hypoglycemic activities of Chlorpropamide.	Approved
Chlorprothixene	The serum concentration of Sitagliptin can be increased when it is combined with Chlorprothixene.	Approved, Withdrawn
Chlorthalidone	The therapeutic efficacy of Sitagliptin can be decreased when used in combination with Chlorthalidone.	Approved
Cholesterol	The serum concentration of Sitagliptin can be increased when it is combined with Cholesterol.	Experimental
Cholic Acid	The serum concentration of Sitagliptin can be decreased when it is combined with Cholic Acid.	Approved
Cilazapril	The serum concentration of Sitagliptin can be increased when it is combined with Cilazapril.	Approved
Cimetidine	The serum concentration of Sitagliptin can be decreased when it is combined with Cimetidine.	Approved
Cinoxacin	Cinoxacin may increase the hypoglycemic activities of Sitagliptin.	Approved, Withdrawn
Ciprofloxacin	The serum concentration of Sitagliptin can be increased when it is combined with Ciprofloxacin.	Approved, Investigational
Cisapride	The serum concentration of Cisapride can be increased when it is combined with Sitagliptin.	Approved, Investigational, Withdrawn
Citalopram	The serum concentration of Sitagliptin can be increased when it is combined with Citalopram.	Approved
Clarithromycin	The therapeutic efficacy of Clarithromycin can be decreased when used in combination with Sitagliptin.	Approved
Clemastine	The metabolism of Sitagliptin can be decreased when combined with Clemastine.	Approved
Clofazimine	The serum concentration of Sitagliptin can be increased when it is combined with Clofazimine.	Approved, Investigational
Clomipramine	The serum concentration of Clomipramine can be increased when it is combined with Sitagliptin.	Approved, Vet Approved
Clopidogrel	The metabolism of Sitagliptin can be decreased when combined with Clopidogrel.	Approved, Nutraceutical
Clotrimazole	The metabolism of Sitagliptin can be decreased when combined with Clotrimazole.	Approved, Vet Approved
Clozapine	The therapeutic efficacy of Sitagliptin can be decreased when used in combination with Clozapine.	Approved
Cobicistat	The metabolism of Sitagliptin can be decreased when combined with Cobicistat.	Approved
Colchicine	The serum concentration of Sitagliptin can be increased when it is combined with Colchicine.	Approved
Colforsin	The serum concentration of Sitagliptin can be increased when it is combined with Colforsin.	Experimental
Conivaptan	The serum concentration of Sitagliptin can be increased when it is combined with Conivaptan.	Approved, Investigational
Conjugated estrogens	The serum concentration of Conjugated Equine Estrogens can be decreased when it is combined with Sitagliptin.	Approved
Corticotropin	The therapeutic efficacy of Sitagliptin can be decreased when used in combination with Corticotropin.	Approved, Vet Approved
Cortisone acetate	The therapeutic efficacy of Sitagliptin can be decreased when used in combination with Cortisone acetate.	Approved
Crizotinib	The metabolism of Sitagliptin can be decreased when combined with Crizotinib.	Approved
Cyclobenzaprine	The serum concentration of Cyclobenzaprine can be increased when it is combined with Sitagliptin.	Approved
Cyclophosphamide	The risk or severity of adverse effects can be increased when Sitagliptin is combined with Cyclophosphamide.	Approved, Investigational
Cyclosporine	The serum concentration of Cyclosporine can be increased when it is combined with Sitagliptin.	Approved, Investigational, Vet Approved
Cyclosporine	The metabolism of Sitagliptin can be decreased when combined with Cyclosporine.	Approved, Investigational, Vet Approved
Cyproterone acetate	The therapeutic efficacy of Sitagliptin can be decreased when used in combination with Cyproterone acetate.	Approved, Investigational
Dabrafenib	The serum concentration of Sitagliptin can be decreased when it is combined with Dabrafenib.	Approved
Daclatasvir	The serum concentration of Sitagliptin can be increased when it is combined with Daclatasvir.	Approved
Dactinomycin	The serum concentration of Sitagliptin can be increased when it is combined with Dactinomycin.	Approved
Danazol	The therapeutic efficacy of Sitagliptin can be decreased when used in combination with Danazol.	Approved
Dapoxetine	Dapoxetine may increase the hypoglycemic activities of Sitagliptin.	Investigational
Darunavir	The metabolism of Sitagliptin can be decreased when combined with Darunavir.	Approved
Dasatinib	The serum concentration of Sitagliptin can be increased when it is combined with Dasatinib.	Approved, Investigational
Daunorubicin	The serum concentration of Sitagliptin can be decreased when it is combined with Daunorubicin.	Approved
Deferasirox	The serum concentration of Sitagliptin can be decreased when it is combined with Deferasirox.	Approved, Investigational
Delavirdine	The serum concentration of Delavirdine can be decreased when it is combined with Sitagliptin.	Approved
Desipramine	The serum concentration of Desipramine can be increased when it is combined with Sitagliptin.	Approved
Desloratadine	The serum concentration of Sitagliptin can be increased when it is combined with Desloratadine.	Approved, Investigational
Desogestrel	The therapeutic efficacy of Sitagliptin can be decreased when used in combination with Desogestrel.	Approved
Desvenlafaxine	Desvenlafaxine may increase the hypoglycemic activities of Sitagliptin.	Approved
Dexamethasone	The serum concentration of Sitagliptin can be decreased when it is combined with Dexamethasone.	Approved, Investigational, Vet Approved
Dextromethorphan	The serum concentration of Sitagliptin can be increased when it is combined with Dextromethorphan.	Approved
Diazoxide	The therapeutic efficacy of Sitagliptin can be decreased when used in combination with Diazoxide.	Approved
Diclofenac	The serum concentration of Sitagliptin can be increased when it is combined with Diclofenac.	Approved, Vet Approved
Dienestrol	The serum concentration of Dienestrol can be decreased when it is combined with Sitagliptin.	Approved
Dienogest	The therapeutic efficacy of Sitagliptin can be decreased when used in combination with Dienogest.	Approved
Diethylstilbestrol	The serum concentration of Diethylstilbestrol can be decreased when it is combined with Sitagliptin.	Approved
Diflunisal	Diflunisal may increase the hypoglycemic activities of Sitagliptin.	Approved
Digoxin	The serum concentration of Digoxin can be increased when it is combined with Sitagliptin.	Approved
Dihydroergotamine	The serum concentration of Dihydroergotamine can be increased when it is combined with Sitagliptin.	Approved
Dihydrotestosterone	Dihydrotestosterone may increase the hypoglycemic activities of Sitagliptin.	Illicit
Diltiazem	The metabolism of Diltiazem can be decreased when combined with Sitagliptin.	Approved
Dipyridamole	The serum concentration of Sitagliptin can be increased when it is combined with Dipyridamole.	Approved
Disopyramide	Sitagliptin may increase the hypoglycemic activities of Disopyramide.	Approved
Dosulepin	The serum concentration of Dosulepin can be increased when it is combined with Sitagliptin.	Approved
Doxazosin	The serum concentration of Sitagliptin can be increased when it is combined with Doxazosin.	Approved
Doxepin	The serum concentration of Doxepin can be increased when it is combined with Sitagliptin.	Approved
Doxorubicin	The serum concentration of Sitagliptin can be decreased when it is combined with Doxorubicin.	Approved, Investigational
Doxycycline	The metabolism of Sitagliptin can be decreased when combined with Doxycycline.	Approved, Investigational, Vet Approved
Dronabinol	The serum concentration of Sitagliptin can be increased when it is combined with Dronabinol.	Approved, Illicit
Dronedarone	The metabolism of Sitagliptin can be decreased when combined with Dronedarone.	Approved
Drospirenone	The therapeutic efficacy of Sitagliptin can be decreased when used in combination with Drospirenone.	Approved
Duloxetine	Duloxetine may increase the hypoglycemic activities of Sitagliptin.	Approved
Dyphylline	The serum concentration of Dyphylline can be decreased when it is combined with Sitagliptin.	Approved
Efavirenz	The serum concentration of Sitagliptin can be decreased when it is combined with Efavirenz.	Approved, Investigational
Elbasvir	The serum concentration of Sitagliptin can be increased when it is combined with Elbasvir.	Approved
Enalapril	The serum concentration of Sitagliptin can be increased when it is combined with Enalapril.	Approved, Vet Approved
Enalaprilat	The risk or severity of adverse effects can be increased when Sitagliptin is combined with Enalaprilat.	Approved
Enfuvirtide	The serum concentration of Enfuvirtide can be increased when it is combined with Sitagliptin.	Approved, Investigational
Enoxacin	Enoxacin may increase the hypoglycemic activities of Sitagliptin.	Approved
Enzalutamide	The serum concentration of Sitagliptin can be decreased when it is combined with Enzalutamide.	Approved
Epinephrine	The therapeutic efficacy of Sitagliptin can be decreased when used in combination with Epinephrine.	Approved, Vet Approved
Ergoloid mesylate	The serum concentration of Ergoloid mesylate can be increased when it is combined with Sitagliptin.	Approved
Ergonovine	The serum concentration of Ergonovine can be increased when it is combined with Sitagliptin.	Approved
Ergotamine	The serum concentration of Ergotamine can be increased when it is combined with Sitagliptin.	Approved
Erythromycin	The metabolism of Sitagliptin can be decreased when combined with Erythromycin.	Approved, Vet Approved
Escitalopram	Escitalopram may increase the hypoglycemic activities of Sitagliptin.	Approved, Investigational
Eslicarbazepine acetate	The serum concentration of Sitagliptin can be decreased when it is combined with Eslicarbazepine acetate.	Approved
Esmirtazapine	The serum concentration of Esmirtazapine can be increased when it is combined with Sitagliptin.	Investigational
Estradiol	The serum concentration of Estradiol can be decreased when it is combined with Sitagliptin.	Approved, Investigational, Vet Approved
Estramustine	The serum concentration of Estramustine can be decreased when it is combined with Sitagliptin.	Approved
Estriol	The serum concentration of Sitagliptin can be decreased when it is combined with Estriol.	Approved, Vet Approved
Estrogens, esterified	The serum concentration of Estrogens, esterified can be decreased when it is combined with Sitagliptin.	Approved
Estrone	The serum concentration of Sitagliptin can be decreased when it is combined with Estrone.	Approved
Estrone sulfate	The serum concentration of Estrone sulfate can be decreased when it is combined with Sitagliptin.	Approved
Etacrynic acid	The therapeutic efficacy of Sitagliptin can be decreased when used in combination with Etacrynic acid.	Approved
Ethinyl Estradiol	The serum concentration of Ethinyl Estradiol can be decreased when it is combined with Sitagliptin.	Approved
Ethynodiol diacetate	The therapeutic efficacy of Sitagliptin can be decreased when used in combination with Ethynodiol diacetate.	Approved
Etonogestrel	The therapeutic efficacy of Sitagliptin can be decreased when used in combination with Etonogestrel.	Approved, Investigational
Etoperidone	Etoperidone may increase the hypoglycemic activities of Sitagliptin.	Approved
Etoposide	The serum concentration of Sitagliptin can be increased when it is combined with Etoposide.	Approved
Etravirine	The serum concentration of Etravirine can be decreased when it is combined with Sitagliptin.	Approved
Everolimus	The therapeutic efficacy of Sitagliptin can be decreased when used in combination with Everolimus.	Approved
Felodipine	The serum concentration of Sitagliptin can be increased when it is combined with Felodipine.	Approved, Investigational
Fentanyl	The serum concentration of Sitagliptin can be increased when it is combined with Fentanyl.	Approved, Illicit, Investigational, Vet Approved
Fexofenadine	The serum concentration of Sitagliptin can be increased when it is combined with Fexofenadine.	Approved
Fidaxomicin	The serum concentration of Sitagliptin can be increased when it is combined with Fidaxomicin.	Approved
Fleroxacin	Fleroxacin may increase the hypoglycemic activities of Sitagliptin.	Approved
Fluconazole	The metabolism of Sitagliptin can be decreased when combined with Fluconazole.	Approved
Fludrocortisone	The therapeutic efficacy of Sitagliptin can be decreased when used in combination with Fludrocortisone.	Approved
Flumequine	Flumequine may increase the hypoglycemic activities of Sitagliptin.	Withdrawn
Fluoxetine	The serum concentration of Sitagliptin can be increased when it is combined with Fluoxetine.	Approved, Vet Approved
Fluoxymesterone	Fluoxymesterone may increase the hypoglycemic activities of Sitagliptin.	Approved, Illicit
Flupentixol	The serum concentration of Sitagliptin can be increased when it is combined with Flupentixol.	Approved, Withdrawn
Fluphenazine	The serum concentration of Sitagliptin can be increased when it is combined with Fluphenazine.	Approved
Flurazepam	The serum concentration of Sitagliptin can be increased when it is combined with Flurazepam.	Approved, Illicit
Fluvoxamine	The metabolism of Sitagliptin can be decreased when combined with Fluvoxamine.	Approved, Investigational
Fosamprenavir	The metabolism of Sitagliptin can be decreased when combined with Fosamprenavir.	Approved
Fosaprepitant	The serum concentration of Sitagliptin can be increased when it is combined with Fosaprepitant.	Approved
Fosinopril	The risk or severity of adverse effects can be increased when Sitagliptin is combined with Fosinopril.	Approved
Fosphenytoin	The metabolism of Sitagliptin can be increased when combined with Fosphenytoin.	Approved
Furazolidone	Furazolidone may increase the hypoglycemic activities of Sitagliptin.	Approved, Vet Approved
Furosemide	The therapeutic efficacy of Sitagliptin can be decreased when used in combination with Furosemide.	Approved, Vet Approved
Fusidic Acid	The serum concentration of Sitagliptin can be increased when it is combined with Fusidic Acid.	Approved
Gatifloxacin	Gatifloxacin may increase the hypoglycemic activities of Sitagliptin.	Approved, Investigational
Gefitinib	The serum concentration of Sitagliptin can be increased when it is combined with Gefitinib.	Approved, Investigational
Gemfibrozil	The metabolism of Sitagliptin can be decreased when combined with Gemfibrozil.	Approved
Gemifloxacin	Gemifloxacin may increase the hypoglycemic activities of Sitagliptin.	Approved, Investigational
Genistein	The serum concentration of Sitagliptin can be increased when it is combined with Genistein.	Investigational
Glibornuride	Sitagliptin may increase the hypoglycemic activities of Glibornuride.	Withdrawn
Gliclazide	Sitagliptin may increase the hypoglycemic activities of Gliclazide.	Approved
Glimepiride	Sitagliptin may increase the hypoglycemic activities of Glimepiride.	Approved
Glipizide	Sitagliptin may increase the hypoglycemic activities of Glipizide.	Approved
Gliquidone	Sitagliptin may increase the hypoglycemic activities of Gliquidone.	Approved
Glisoxepide	Sitagliptin may increase the hypoglycemic activities of Glisoxepide.	Approved
Glyburide	Sitagliptin may increase the hypoglycemic activities of Glyburide.	Approved
Goserelin	The therapeutic efficacy of Sitagliptin can be decreased when used in combination with Goserelin.	Approved
Gramicidin D	The serum concentration of Sitagliptin can be increased when it is combined with Gramicidin D.	Approved
Grepafloxacin	The serum concentration of Sitagliptin can be increased when it is combined with Grepafloxacin.	Withdrawn
Haloperidol	The serum concentration of Sitagliptin can be increased when it is combined with Haloperidol.	Approved
Hexestrol	The serum concentration of Hexestrol can be decreased when it is combined with Sitagliptin.	Withdrawn
Histrelin	The therapeutic efficacy of Sitagliptin can be decreased when used in combination with Histrelin.	Approved
Hydracarbazine	Hydracarbazine may increase the hypoglycemic activities of Sitagliptin.	Experimental
Hydrochlorothiazide	The therapeutic efficacy of Sitagliptin can be decreased when used in combination with Hydrochlorothiazide.	Approved, Vet Approved
Hydrocortisone	The serum concentration of Sitagliptin can be increased when it is combined with Hydrocortisone.	Approved, Vet Approved
Hydroflumethiazide	The therapeutic efficacy of Sitagliptin can be decreased when used in combination with Hydroflumethiazide.	Approved
Hydroxyprogesterone caproate	The therapeutic efficacy of Sitagliptin can be decreased when used in combination with Hydroxyprogesterone caproate.	Approved
Idelalisib	The serum concentration of Sitagliptin can be increased when it is combined with Idelalisib.	Approved
Iloperidone	The therapeutic efficacy of Sitagliptin can be decreased when used in combination with Iloperidone.	Approved
Imatinib	The metabolism of Sitagliptin can be decreased when combined with Imatinib.	Approved
Imidapril	The risk or severity of adverse effects can be increased when Sitagliptin is combined with Imidapril.	Investigational
Imipramine	The serum concentration of Imipramine can be increased when it is combined with Sitagliptin.	Approved
Indalpine	Indalpine may increase the hypoglycemic activities of Sitagliptin.	Investigational, Withdrawn
Indapamide	The therapeutic efficacy of Sitagliptin can be decreased when used in combination with Indapamide.	Approved
Indinavir	The metabolism of Sitagliptin can be decreased when combined with Indinavir.	Approved
Indomethacin	The serum concentration of Sitagliptin can be increased when it is combined with Indomethacin.	Approved, Investigational
Insulin Aspart	Sitagliptin may increase the hypoglycemic activities of Insulin Aspart.	Approved
Insulin Detemir	Sitagliptin may increase the hypoglycemic activities of Insulin Detemir.	Approved
Insulin Glargine	Sitagliptin may increase the hypoglycemic activities of Insulin Glargine.	Approved
Insulin Glulisine	Sitagliptin may increase the hypoglycemic activities of Insulin Glulisine.	Approved
Insulin Human	Sitagliptin may increase the hypoglycemic activities of Insulin Human.	Approved, Investigational
Insulin Lispro	Sitagliptin may increase the hypoglycemic activities of Insulin Lispro.	Approved
Insulin Pork	Sitagliptin may increase the hypoglycemic activities of Insulin Pork.	Approved
Iproclozide	Iproclozide may increase the hypoglycemic activities of Sitagliptin.	Withdrawn
Iproniazid	Iproniazid may increase the hypoglycemic activities of Sitagliptin.	Withdrawn
Irbesartan	The metabolism of Sitagliptin can be decreased when combined with Irbesartan.	Approved, Investigational
Isavuconazonium	The metabolism of Sitagliptin can be decreased when combined with Isavuconazonium.	Approved, Investigational
Isocarboxazid	Isocarboxazid may increase the hypoglycemic activities of Sitagliptin.	Approved
Isradipine	The metabolism of Sitagliptin can be decreased when combined with Isradipine.	Approved
Itraconazole	The metabolism of Sitagliptin can be decreased when combined with Itraconazole.	Approved, Investigational
Ivacaftor	The serum concentration of Sitagliptin can be increased when it is combined with Ivacaftor.	Approved
Ivermectin	The serum concentration of Sitagliptin can be increased when it is combined with Ivermectin.	Approved, Vet Approved
Ketamine	The serum concentration of Sitagliptin can be increased when it is combined with Ketamine.	Approved, Vet Approved
Ketoconazole	The metabolism of Sitagliptin can be decreased when combined with Ketoconazole.	Approved, Investigational
Lanreotide	The therapeutic efficacy of Sitagliptin can be decreased when used in combination with Lanreotide.	Approved
Lansoprazole	The serum concentration of Sitagliptin can be increased when it is combined with Lansoprazole.	Approved, Investigational
Lapatinib	The serum concentration of Sitagliptin can be increased when it is combined with Lapatinib.	Approved, Investigational
Leuprolide	The therapeutic efficacy of Sitagliptin can be decreased when used in combination with Leuprolide.	Approved, Investigational
Levofloxacin	The serum concentration of Sitagliptin can be increased when it is combined with Levofloxacin.	Approved, Investigational
Levomilnacipran	Levomilnacipran may increase the hypoglycemic activities of Sitagliptin.	Approved
Levonorgestrel	The therapeutic efficacy of Sitagliptin can be decreased when used in combination with Levonorgestrel.	Approved, Investigational
Levothyroxine	The serum concentration of Sitagliptin can be decreased when it is combined with Levothyroxine.	Approved
Lidocaine	The serum concentration of Sitagliptin can be increased when it is combined with Lidocaine.	Approved, Vet Approved
Liothyronine	The serum concentration of Sitagliptin can be decreased when it is combined with Liothyronine.	Approved, Vet Approved
Liotrix	The serum concentration of Sitagliptin can be decreased when it is combined with Liotrix.	Approved
Lipoic Acid	Lipoic Acid may increase the hypoglycemic activities of Sitagliptin.	Approved, Nutraceutical
Lisinopril	The serum concentration of Sitagliptin can be increased when it is combined with Lisinopril.	Approved, Investigational
Lomefloxacin	Lomefloxacin may increase the hypoglycemic activities of Sitagliptin.	Approved
Lomitapide	The serum concentration of Sitagliptin can be increased when it is combined with Lomitapide.	Approved
Loperamide	The serum concentration of Sitagliptin can be increased when it is combined with Loperamide.	Approved
Lopinavir	The metabolism of Sitagliptin can be decreased when combined with Lopinavir.	Approved
Loratadine	The serum concentration of Sitagliptin can be increased when it is combined with Loratadine.	Approved
Losartan	The serum concentration of Sitagliptin can be increased when it is combined with Losartan.	Approved
Lovastatin	The serum concentration of Lovastatin can be increased when it is combined with Sitagliptin.	Approved, Investigational
Luliconazole	The serum concentration of Sitagliptin can be increased when it is combined with Luliconazole.	Approved
Lumacaftor	The serum concentration of Sitagliptin can be increased when it is combined with Lumacaftor.	Approved
Lurasidone	The therapeutic efficacy of Sitagliptin can be decreased when used in combination with Lurasidone.	Approved
Maprotiline	The serum concentration of Sitagliptin can be increased when it is combined with Maprotiline.	Approved
Mebanazine	Mebanazine may increase the hypoglycemic activities of Sitagliptin.	Withdrawn
Mebendazole	The serum concentration of Sitagliptin can be increased when it is combined with Mebendazole.	Approved, Vet Approved
Mecasermin	Sitagliptin may increase the hypoglycemic activities of Mecasermin.	Approved, Investigational
Medroxyprogesterone acetate	The therapeutic efficacy of Sitagliptin can be decreased when used in combination with Medroxyprogesterone acetate.	Approved, Investigational
Mefloquine	The serum concentration of Sitagliptin can be increased when it is combined with Mefloquine.	Approved
Megestrol acetate	The serum concentration of Sitagliptin can be increased when it is combined with Megestrol acetate.	Approved, Vet Approved
Meprobamate	The serum concentration of Sitagliptin can be increased when it is combined with Meprobamate.	Approved, Illicit
Mesalazine	Mesalazine may increase the hypoglycemic activities of Sitagliptin.	Approved
Mestranol	The serum concentration of Mestranol can be decreased when it is combined with Sitagliptin.	Approved
Methadone	The serum concentration of Sitagliptin can be increased when it is combined with Methadone.	Approved
Methallenestril	The serum concentration of Methallenestril can be decreased when it is combined with Sitagliptin.	Experimental
Methotrimeprazine	The therapeutic efficacy of Sitagliptin can be decreased when used in combination with Methotrimeprazine.	Approved
Methyclothiazide	The therapeutic efficacy of Sitagliptin can be decreased when used in combination with Methyclothiazide.	Approved
Methylene blue	Methylene blue may increase the hypoglycemic activities of Sitagliptin.	Investigational
Methylprednisolone	The therapeutic efficacy of Sitagliptin can be decreased when used in combination with Methylprednisolone.	Approved, Vet Approved
Methyltestosterone	Methyltestosterone may increase the hypoglycemic activities of Sitagliptin.	Approved
Metolazone	The therapeutic efficacy of Sitagliptin can be decreased when used in combination with Metolazone.	Approved
Metoprolol	The serum concentration of Sitagliptin can be increased when it is combined with Metoprolol.	Approved, Investigational
Mibefradil	The serum concentration of Sitagliptin can be increased when it is combined with Mibefradil.	Withdrawn
Miconazole	The serum concentration of Sitagliptin can be increased when it is combined with Miconazole.	Approved, Investigational, Vet Approved
Midazolam	The serum concentration of Midazolam can be increased when it is combined with Sitagliptin.	Approved, Illicit
Mifepristone	The serum concentration of Sitagliptin can be increased when it is combined with Mifepristone.	Approved, Investigational
Milnacipran	Milnacipran may increase the hypoglycemic activities of Sitagliptin.	Approved
Minaprine	Minaprine may increase the hypoglycemic activities of Sitagliptin.	Approved
Mirtazapine	The serum concentration of Mirtazapine can be increased when it is combined with Sitagliptin.	Approved
Mitomycin	The serum concentration of Sitagliptin can be increased when it is combined with Mitomycin.	Approved
Mitotane	The serum concentration of Sitagliptin can be decreased when it is combined with Mitotane.	Approved
Mitoxantrone	The serum concentration of Sitagliptin can be decreased when it is combined with Mitoxantrone.	Approved, Investigational
Moclobemide	Moclobemide may increase the hypoglycemic activities of Sitagliptin.	Approved
Modafinil	The serum concentration of Sitagliptin can be decreased when it is combined with Modafinil.	Approved, Investigational
Moexipril	The risk or severity of adverse effects can be increased when Sitagliptin is combined with Moexipril.	Approved
Morphine	The serum concentration of Sitagliptin can be increased when it is combined with Morphine.	Approved, Investigational
Moxifloxacin	Moxifloxacin may increase the hypoglycemic activities of Sitagliptin.	Approved, Investigational
Nafcillin	The serum concentration of Sitagliptin can be decreased when it is combined with Nafcillin.	Approved
Nalidixic Acid	Nalidixic Acid may increase the hypoglycemic activities of Sitagliptin.	Approved
Naltrexone	The serum concentration of Sitagliptin can be increased when it is combined with Naltrexone.	Approved, Investigational, Vet Approved
Naringenin	The serum concentration of Sitagliptin can be increased when it is combined with Naringenin.	Experimental
Nateglinide	Sitagliptin may increase the hypoglycemic activities of Nateglinide.	Approved, Investigational
NCX 4016	NCX 4016 may increase the hypoglycemic activities of Sitagliptin.	Investigational
Nefazodone	The serum concentration of Nefazodone can be increased when it is combined with Sitagliptin.	Approved, Withdrawn
Nelfinavir	The metabolism of Sitagliptin can be decreased when combined with Nelfinavir.	Approved
Neostigmine	The serum concentration of Sitagliptin can be increased when it is combined with Neostigmine.	Approved, Vet Approved
Netupitant	The serum concentration of Sitagliptin can be increased when it is combined with Netupitant.	Approved
Nevirapine	The metabolism of Sitagliptin can be increased when combined with Nevirapine.	Approved
Niacin	The therapeutic efficacy of Sitagliptin can be decreased when used in combination with Niacin.	Approved, Investigational, Nutraceutical
Nialamide	Nialamide may increase the hypoglycemic activities of Sitagliptin.	Withdrawn
Nicardipine	The serum concentration of Sitagliptin can be increased when it is combined with Nicardipine.	Approved
Nifedipine	The serum concentration of Sitagliptin can be decreased when it is combined with Nifedipine.	Approved
Nilotinib	The metabolism of Sitagliptin can be decreased when combined with Nilotinib.	Approved, Investigational
Nisoldipine	The serum concentration of Sitagliptin can be increased when it is combined with Nisoldipine.	Approved
Nitrazepam	The serum concentration of Sitagliptin can be increased when it is combined with Nitrazepam.	Approved
Nitrendipine	The serum concentration of Sitagliptin can be increased when it is combined with Nitrendipine.	Approved
Nitroaspirin	Nitroaspirin may increase the hypoglycemic activities of Sitagliptin.	Investigational
Norethisterone	The serum concentration of Sitagliptin can be decreased when it is combined with Norethisterone.	Approved
Norfloxacin	Norfloxacin may increase the hypoglycemic activities of Sitagliptin.	Approved
Norgestimate	The therapeutic efficacy of Sitagliptin can be decreased when used in combination with Norgestimate.	Approved
Nortriptyline	The serum concentration of Nortriptyline can be increased when it is combined with Sitagliptin.	Approved
Octamoxin	Octamoxin may increase the hypoglycemic activities of Sitagliptin.	Withdrawn
Octreotide	The therapeutic efficacy of Sitagliptin can be decreased when used in combination with Octreotide.	Approved, Investigational
Ofloxacin	Ofloxacin may increase the hypoglycemic activities of Sitagliptin.	Approved
Olanzapine	The therapeutic efficacy of Sitagliptin can be decreased when used in combination with Olanzapine.	Approved, Investigational
Olaparib	The metabolism of Sitagliptin can be decreased when combined with Olaparib.	Approved
Olsalazine	Olsalazine may increase the hypoglycemic activities of Sitagliptin.	Approved
Omapatrilat	The risk or severity of adverse effects can be increased when Sitagliptin is combined with Omapatrilat.	Investigational
Omeprazole	The serum concentration of Sitagliptin can be increased when it is combined with Omeprazole.	Approved, Investigational, Vet Approved
Opipramol	The serum concentration of Opipramol can be increased when it is combined with Sitagliptin.	Investigational
Osimertinib	The serum concentration of Sitagliptin can be increased when it is combined with Osimertinib.	Approved
Oxandrolone	Oxandrolone may increase the hypoglycemic activities of Sitagliptin.	Approved, Investigational
Oxymetholone	Oxymetholone may increase the hypoglycemic activities of Sitagliptin.	Approved, Illicit
P-Nitrophenol	The serum concentration of Sitagliptin can be increased when it is combined with P-Nitrophenol.	Experimental
Paclitaxel	The serum concentration of Sitagliptin can be increased when it is combined with Paclitaxel.	Approved, Vet Approved
Palbociclib	The serum concentration of Sitagliptin can be increased when it is combined with Palbociclib.	Approved
Paliperidone	The therapeutic efficacy of Sitagliptin can be decreased when used in combination with Paliperidone.	Approved
Palmitic Acid	The serum concentration of Sitagliptin can be increased when it is combined with Palmitic Acid.	Experimental
Pantoprazole	The serum concentration of Sitagliptin can be increased when it is combined with Pantoprazole.	Approved
Pargyline	Pargyline may increase the hypoglycemic activities of Sitagliptin.	Approved
Paroxetine	The serum concentration of Sitagliptin can be increased when it is combined with Paroxetine.	Approved, Investigational
Pasireotide	The therapeutic efficacy of Sitagliptin can be decreased when used in combination with Pasireotide.	Approved
Pazufloxacin	Pazufloxacin may increase the hypoglycemic activities of Sitagliptin.	Investigational
Pefloxacin	Pefloxacin may increase the hypoglycemic activities of Sitagliptin.	Approved
Pegvisomant	Pegvisomant may increase the hypoglycemic activities of Sitagliptin.	Approved
Pentamidine	The therapeutic efficacy of Sitagliptin can be decreased when used in combination with Pentamidine.	Approved
Pentobarbital	The metabolism of Sitagliptin can be increased when combined with Pentobarbital.	Approved, Vet Approved
Perindopril	The serum concentration of Sitagliptin can be increased when it is combined with Perindopril.	Approved
Pethidine	The risk or severity of adverse effects can be increased when Sitagliptin is combined with Pethidine.	Approved
Phenelzine	Phenelzine may increase the hypoglycemic activities of Sitagliptin.	Approved
Pheniprazine	Pheniprazine may increase the hypoglycemic activities of Sitagliptin.	Withdrawn
Phenobarbital	The metabolism of Sitagliptin can be increased when combined with Phenobarbital.	Approved
Phenoxypropazine	Phenoxypropazine may increase the hypoglycemic activities of Sitagliptin.	Withdrawn
Phenytoin	The metabolism of Sitagliptin can be increased when combined with Phenytoin.	Approved, Vet Approved
Pimozide	The serum concentration of Pimozide can be increased when it is combined with Sitagliptin.	Approved
Pioglitazone	The metabolism of Sitagliptin can be decreased when combined with Pioglitazone.	Approved, Investigational
Piperazine	The therapeutic efficacy of Sitagliptin can be decreased when used in combination with Piperazine.	Approved, Vet Approved
Pipotiazine	The therapeutic efficacy of Sitagliptin can be decreased when used in combination with Pipotiazine.	Approved
Pirlindole	Pirlindole may increase the hypoglycemic activities of Sitagliptin.	Approved
Pivhydrazine	Pivhydrazine may increase the hypoglycemic activities of Sitagliptin.	Withdrawn
Platelet Activating Factor	The serum concentration of Sitagliptin can be decreased when it is combined with Platelet Activating Factor.	Experimental
Polythiazide	The therapeutic efficacy of Sitagliptin can be decreased when used in combination with Polythiazide.	Approved
Ponatinib	The serum concentration of Sitagliptin can be increased when it is combined with Ponatinib.	Approved
Posaconazole	The metabolism of Sitagliptin can be decreased when combined with Posaconazole.	Approved, Investigational, Vet Approved
Pravastatin	The serum concentration of Sitagliptin can be increased when it is combined with Pravastatin.	Approved
Prazosin	The serum concentration of Sitagliptin can be increased when it is combined with Prazosin.	Approved
Prednisolone	The therapeutic efficacy of Sitagliptin can be decreased when used in combination with Prednisolone.	Approved, Vet Approved
Prednisone	The serum concentration of Sitagliptin can be increased when it is combined with Prednisone.	Approved, Vet Approved
Primidone	The metabolism of Sitagliptin can be increased when combined with Primidone.	Approved, Vet Approved
Probenecid	The serum concentration of Sitagliptin can be increased when it is combined with Probenecid.	Approved
Progesterone	The serum concentration of Sitagliptin can be decreased when it is combined with Progesterone.	Approved, Vet Approved
Promethazine	The serum concentration of Sitagliptin can be increased when it is combined with Promethazine.	Approved
Propafenone	The serum concentration of Sitagliptin can be increased when it is combined with Propafenone.	Approved
Propranolol	The serum concentration of Sitagliptin can be increased when it is combined with Propranolol.	Approved, Investigational
Protriptyline	The serum concentration of Protriptyline can be increased when it is combined with Sitagliptin.	Approved
Prulifloxacin	Prulifloxacin may increase the hypoglycemic activities of Sitagliptin.	Investigational
Quercetin	The serum concentration of Sitagliptin can be increased when it is combined with Quercetin.	Experimental
Quetiapine	The therapeutic efficacy of Sitagliptin can be decreased when used in combination with Quetiapine.	Approved
Quinacrine	The serum concentration of Sitagliptin can be increased when it is combined with Quinacrine.	Approved
Quinapril	The risk or severity of adverse effects can be increased when Sitagliptin is combined with Quinapril.	Approved, Investigational
Quinethazone	The therapeutic efficacy of Sitagliptin can be decreased when used in combination with Quinethazone.	Approved
Quinidine	The serum concentration of Sitagliptin can be increased when it is combined with Quinidine.	Approved
Quinine	The serum concentration of Sitagliptin can be increased when it is combined with Quinine.	Approved
Rabeprazole	The metabolism of Sitagliptin can be decreased when combined with Rabeprazole.	Approved, Investigational
Ramipril	The risk or severity of adverse effects can be increased when Sitagliptin is combined with Ramipril.	Approved
Ranitidine	The serum concentration of Sitagliptin can be increased when it is combined with Ranitidine.	Approved
Ranolazine	The serum concentration of Sitagliptin can be increased when it is combined with Ranolazine.	Approved, Investigational
Rasagiline	Rasagiline may increase the hypoglycemic activities of Sitagliptin.	Approved
Reboxetine	The serum concentration of Sitagliptin can be increased when it is combined with Reboxetine.	Approved, Investigational
Regorafenib	The serum concentration of Sitagliptin can be increased when it is combined with Regorafenib.	Approved
Repaglinide	Sitagliptin may increase the hypoglycemic activities of Repaglinide.	Approved, Investigational
Rescinnamine	The risk or severity of adverse effects can be increased when Sitagliptin is combined with Rescinnamine.	Approved
Reserpine	The serum concentration of Sitagliptin can be decreased when it is combined with Reserpine.	Approved
Rifabutin	The metabolism of Sitagliptin can be increased when combined with Rifabutin.	Approved
Rifampicin	The metabolism of Sitagliptin can be increased when combined with Rifampicin.	Approved
Rifapentine	The metabolism of Sitagliptin can be increased when combined with Rifapentine.	Approved
Rilpivirine	The serum concentration of Sitagliptin can be increased when it is combined with Rilpivirine.	Approved
Riociguat	The serum concentration of Riociguat can be increased when it is combined with Sitagliptin.	Approved
Risperidone	The therapeutic efficacy of Sitagliptin can be decreased when used in combination with Risperidone.	Approved, Investigational
Ritonavir	The metabolism of Sitagliptin can be decreased when combined with Ritonavir.	Approved, Investigational
Rolapitant	The serum concentration of Sitagliptin can be increased when it is combined with Rolapitant.	Approved
Rosiglitazone	The metabolism of Sitagliptin can be decreased when combined with Rosiglitazone.	Approved, Investigational
Rosoxacin	Rosoxacin may increase the hypoglycemic activities of Sitagliptin.	Approved
Rosuvastatin	The serum concentration of Rosuvastatin can be increased when it is combined with Sitagliptin.	Approved
Safrazine	Safrazine may increase the hypoglycemic activities of Sitagliptin.	Withdrawn
Salicylic acid	Salicylic acid may increase the hypoglycemic activities of Sitagliptin.	Approved, Vet Approved
Saquinavir	The metabolism of Sitagliptin can be decreased when combined with Saquinavir.	Approved, Investigational
Scopolamine	The serum concentration of Sitagliptin can be increased when it is combined with Scopolamine.	Approved
Secobarbital	The metabolism of Sitagliptin can be increased when combined with Secobarbital.	Approved, Vet Approved
Selegiline	Selegiline may increase the hypoglycemic activities of Sitagliptin.	Approved, Investigational, Vet Approved
Sertraline	The serum concentration of Sitagliptin can be increased when it is combined with Sertraline.	Approved
Sildenafil	The serum concentration of Sildenafil can be increased when it is combined with Sitagliptin.	Approved, Investigational
Siltuximab	The serum concentration of Sitagliptin can be decreased when it is combined with Siltuximab.	Approved
Simeprevir	The serum concentration of Simeprevir can be increased when it is combined with Sitagliptin.	Approved
Simvastatin	The serum concentration of Simvastatin can be increased when it is combined with Sitagliptin.	Approved
Sirolimus	The serum concentration of Sitagliptin can be decreased when it is combined with Sirolimus.	Approved, Investigational
Sorafenib	The serum concentration of Sitagliptin can be increased when it is combined with Sorafenib.	Approved, Investigational
Sparfloxacin	Sparfloxacin may increase the hypoglycemic activities of Sitagliptin.	Approved
Spirapril	The risk or severity of adverse effects can be increased when Sitagliptin is combined with Spirapril.	Approved
Spironolactone	The serum concentration of Sitagliptin can be increased when it is combined with Spironolactone.	Approved
St. John's Wort	The metabolism of Sitagliptin can be increased when combined with St. John's Wort.	Nutraceutical
Stanozolol	Stanozolol may increase the hypoglycemic activities of Sitagliptin.	Approved, Vet Approved
Staurosporine	The serum concentration of Sitagliptin can be increased when it is combined with Staurosporine.	Experimental
Stiripentol	The serum concentration of Sitagliptin can be increased when it is combined with Stiripentol.	Approved
Streptozocin	The serum concentration of Sitagliptin can be decreased when it is combined with Streptozocin.	Approved
Sulfadiazine	Sitagliptin may increase the hypoglycemic activities of Sulfadiazine.	Approved, Vet Approved
Sulfamethoxazole	The metabolism of Sitagliptin can be decreased when combined with Sulfamethoxazole.	Approved
Sulfinpyrazone	The serum concentration of Sitagliptin can be increased when it is combined with Sulfinpyrazone.	Approved
Sulfisoxazole	The metabolism of Sitagliptin can be decreased when combined with Sulfisoxazole.	Approved, Vet Approved
Sumatriptan	The serum concentration of Sitagliptin can be increased when it is combined with Sumatriptan.	Approved, Investigational
Sunitinib	The serum concentration of Sitagliptin can be increased when it is combined with Sunitinib.	Approved, Investigational
Synthetic Conjugated Estrogens, A	The serum concentration of Synthetic Conjugated Estrogens, A can be decreased when it is combined with Sitagliptin.	Approved
Tacrine	The serum concentration of Sitagliptin can be increased when it is combined with Tacrine.	Withdrawn
Tacrolimus	The metabolism of Tacrolimus can be decreased when combined with Sitagliptin.	Approved, Investigational
Tacrolimus	The serum concentration of Sitagliptin can be decreased when it is combined with Tacrolimus.	Approved, Investigational
Tamoxifen	The serum concentration of Sitagliptin can be decreased when it is combined with Tamoxifen.	Approved
Taurocholic Acid	The serum concentration of Sitagliptin can be increased when it is combined with Taurocholic Acid.	Experimental
Telaprevir	The metabolism of Sitagliptin can be decreased when combined with Telaprevir.	Withdrawn
Telithromycin	The metabolism of Sitagliptin can be decreased when combined with Telithromycin.	Approved
Telmisartan	The serum concentration of Sitagliptin can be increased when it is combined with Telmisartan.	Approved, Investigational
Temafloxacin	Temafloxacin may increase the hypoglycemic activities of Sitagliptin.	Withdrawn
Temocapril	The risk or severity of adverse effects can be increased when Sitagliptin is combined with Temocapril.	Experimental, Investigational
Temsirolimus	The risk or severity of adverse effects can be increased when Sitagliptin is combined with Temsirolimus.	Approved
Terazosin	The serum concentration of Sitagliptin can be increased when it is combined with Terazosin.	Approved
Terfenadine	The serum concentration of Sitagliptin can be increased when it is combined with Terfenadine.	Withdrawn
Teriflunomide	The metabolism of Sitagliptin can be decreased when combined with Teriflunomide.	Approved
Tesmilifene	The serum concentration of Sitagliptin can be decreased when it is combined with Tesmilifene.	Investigational
Testosterone	The serum concentration of Sitagliptin can be increased when it is combined with Testosterone.	Approved, Investigational
Theophylline	The serum concentration of Theophylline can be decreased when it is combined with Sitagliptin.	Approved
Tianeptine	The serum concentration of Tianeptine can be increased when it is combined with Sitagliptin.	Approved
Ticagrelor	The serum concentration of Sitagliptin can be increased when it is combined with Ticagrelor.	Approved
Ticlopidine	The metabolism of Sitagliptin can be decreased when combined with Ticlopidine.	Approved
Tipranavir	The serum concentration of Sitagliptin can be decreased when it is combined with Tipranavir.	Approved, Investigational
Tocilizumab	The serum concentration of Sitagliptin can be decreased when it is combined with Tocilizumab.	Approved
Tolazamide	Sitagliptin may increase the hypoglycemic activities of Tolazamide.	Approved
Tolbutamide	Sitagliptin may increase the hypoglycemic activities of Tolbutamide.	Approved
Toloxatone	Toloxatone may increase the hypoglycemic activities of Sitagliptin.	Approved
Tolvaptan	The serum concentration of Sitagliptin can be increased when it is combined with Tolvaptan.	Approved
Torasemide	The therapeutic efficacy of Sitagliptin can be decreased when used in combination with Torasemide.	Approved
Trandolapril	The risk or severity of adverse effects can be increased when Sitagliptin is combined with Trandolapril.	Approved
Trans-2-Phenylcyclopropylamine	Trans-2-Phenylcyclopropylamine may increase the hypoglycemic activities of Sitagliptin.	Experimental
Tranylcypromine	Tranylcypromine may increase the hypoglycemic activities of Sitagliptin.	Approved
Trazodone	The serum concentration of Sitagliptin can be decreased when it is combined with Trazodone.	Approved, Investigational
Triamcinolone	The therapeutic efficacy of Sitagliptin can be decreased when used in combination with Triamcinolone.	Approved, Vet Approved
Triazolam	The serum concentration of Triazolam can be increased when it is combined with Sitagliptin.	Approved
Trichlormethiazide	The therapeutic efficacy of Sitagliptin can be decreased when used in combination with Trichlormethiazide.	Approved, Vet Approved
Trifluoperazine	The serum concentration of Sitagliptin can be increased when it is combined with Trifluoperazine.	Approved
Triflupromazine	The serum concentration of Sitagliptin can be increased when it is combined with Triflupromazine.	Approved, Vet Approved
Trimethoprim	The serum concentration of Sitagliptin can be decreased when it is combined with Trimethoprim.	Approved, Vet Approved
Trimipramine	The serum concentration of Trimipramine can be increased when it is combined with Sitagliptin.	Approved
Triptorelin	The therapeutic efficacy of Sitagliptin can be decreased when used in combination with Triptorelin.	Approved, Vet Approved
Trovafloxacin	Trovafloxacin may increase the hypoglycemic activities of Sitagliptin.	Approved, Withdrawn
Valproic Acid	The serum concentration of Valproic Acid can be decreased when it is combined with Sitagliptin.	Approved, Investigational
Venlafaxine	The metabolism of Sitagliptin can be decreased when combined with Venlafaxine.	Approved
Verapamil	The metabolism of Verapamil can be decreased when combined with Sitagliptin.	Approved
Vinblastine	The serum concentration of Sitagliptin can be decreased when it is combined with Vinblastine.	Approved
Vincristine	The serum concentration of Sitagliptin can be decreased when it is combined with Vincristine.	Approved, Investigational
Vinorelbine	The serum concentration of Sitagliptin can be increased when it is combined with Vinorelbine.	Approved, Investigational
Voriconazole	The metabolism of Sitagliptin can be decreased when combined with Voriconazole.	Approved, Investigational
Vorinostat	The therapeutic efficacy of Sitagliptin can be decreased when used in combination with Vorinostat.	Approved, Investigational
Zidovudine	The serum concentration of Zidovudine can be decreased when it is combined with Sitagliptin.	Approved
Zimelidine	The serum concentration of Sitagliptin can be increased when it is combined with Zimelidine.	Withdrawn
Ziprasidone	The metabolism of Sitagliptin can be decreased when combined with Ziprasidone.	Approved

Food Interactions

Can be administered without regard to food

References

Synthesis Reference

Nurit Perlman, Marina Etinger, Valerie Niddam-Hildesheim, Mili Abramov, "Preparation of sitagliptin intermediate." U.S. Patent US20090192326, issued July 30, 2009.

US20090192326

General References

Herman GA, Stevens C, Van Dyck K, Bergman A, Yi B, De Smet M, Snyder K, Hilliard D, Tanen M, Tanaka W, Wang AQ, Zeng W, Musson D, Winchell G, Davies MJ, Ramael S, Gottesdiener KM, Wagner JA: Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: results from two randomized, double-blind, placebo-controlled studies with single oral doses. Clin Pharmacol Ther. 2005 Dec;78(6):675-88. [PubMed:16338283 ]
Herman GA, Bergman A, Liu F, Stevens C, Wang AQ, Zeng W, Chen L, Snyder K, Hilliard D, Tanen M, Tanaka W, Meehan AG, Lasseter K, Dilzer S, Blum R, Wagner JA: Pharmacokinetics and pharmacodynamic effects of the oral DPP-4 inhibitor sitagliptin in middle-aged obese subjects. J Clin Pharmacol. 2006 Aug;46(8):876-86. [PubMed:16855072 ]
Karasik A, Aschner P, Katzeff H, Davies MJ, Stein PP: Sitagliptin, a DPP-4 inhibitor for the treatment of patients with type 2 diabetes: a review of recent clinical trials. Curr Med Res Opin. 2008 Feb;24(2):489-96. doi: 10.1185/030079908X261069 . [PubMed:18182122 ]
Pratley RE, Salsali A: Inhibition of DPP-4: a new therapeutic approach for the treatment of type 2 diabetes. Curr Med Res Opin. 2007 Apr;23(4):919-31. [PubMed:17407649 ]
Bergman A, Ebel D, Liu F, Stone J, Wang A, Zeng W, Chen L, Dilzer S, Lasseter K, Herman G, Wagner J, Krishna R: Absolute bioavailability of sitagliptin, an oral dipeptidyl peptidase-4 inhibitor, in healthy volunteers. Biopharm Drug Dispos. 2007 Sep;28(6):315-22. [PubMed:17575559 ]
Richter B, Bandeira-Echtler E, Bergerhoff K, Lerch C: Emerging role of dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes. Vasc Health Risk Manag. 2008;4(4):753-68. [PubMed:19065993 ]

External Links

Resource	Link
Human Metabolome Database (HMDB)	HMDB15390
PubChem Compound	4369359
PubChem Substance	46505822
ChemSpider	3571948
BindingDB	11162
ChEBI	40237
ChEMBL	CHEMBL1422
Therapeutic Targets Database	DAP000639
PharmGKB	PA164748978
HET	715
Drug Product Database	20179
RxList	http://www.rxlist.com/cgi/generic/januvia.htm
Drugs.com	http://www.drugs.com/cdi/sitagliptin.html
Wikipedia	Sitagliptin

ATC Codes

A10BH51 — Sitagliptin and simvastatin

A10BD12 — Pioglitazone and sitagliptin

A10BH01 — Sitagliptin

A10BD07 — Metformin and sitagliptin

AHFS Codes

Not Available

PDB Entries

Not Available

FDA label

Not Available

MSDS

Not Available

Clinical Trials

Phase	Status	Purpose	Conditions	Count
0	Completed	Basic Science	Healthy Volunteers	1
0	Completed	Treatment	Congestive Heart Failure (CHF)	1
0	Withdrawn	Treatment	Type 2 Diabetes Mellitus	1
1	Completed	Not Available	BMI >30 kg/m2	1
1	Completed	Not Available	Diabetes Mellitus (DM)	1
1	Completed	Not Available	Healthy Volunteers / Pharmacokinetics of ASP1941	1
1	Completed	Not Available	Type 2 Diabetes Mellitus	1
1	Completed	Diagnostic	Cystic Fibrosis (CF)	1
1	Completed	Diagnostic	Type 2 Diabetes Mellitus	2
1	Completed	Other	Healthy Volunteers	1
1	Completed	Treatment	Diabetes Mellitus (DM) / Gastroparesis	1
1	Completed	Treatment	Diabetes, Diabetes Mellitus Type 1	1
1	Completed	Treatment	Diabetes, Diabetes Mellitus Type 1 / Type 2 Diabetes Mellitus	1
1	Completed	Treatment	Healthy Volunteers	1
1	Completed	Treatment	Liver Insufficiency	1
1	Completed	Treatment	Type 2 Diabetes Mellitus	23
1	Completed	Treatment	Type2 Diabetes Mellitus	1
1	Not Yet Recruiting	Basic Science	Type 2 Diabetes Mellitus	1
1	Recruiting	Basic Science	Healthy Volunteers	1
1	Recruiting	Treatment	Hepato Carcinoma	1
1	Terminated	Treatment	Chronic Hepatitis C Infection	1
1	Unknown Status	Treatment	Type 2 Diabetes Mellitus	1
1, 2	Completed	Treatment	Type 2 Diabetes Mellitus	1
1, 2	Unknown Status	Treatment	Diabetes, Diabetes Mellitus Type 1	1
2	Active Not Recruiting	Treatment	Acute Lymphocytic Leukemia (ALL) / Acute Myeloid Leukaemias (AML) / Hematopoetic Myelodysplasia / Leukemia, Myelogenous, Chronic / Non-Hodgkin's Lymphoma (NHL)	1
2	Active Not Recruiting	Treatment	Diabetes, Diabetes Mellitus Type 1	1
2	Active Not Recruiting	Treatment	Graft Versus Host Disease (GVHD) / Hematopoietic Stem Cell Transplantation (HSCT)	1
2	Completed	Not Available	Type 2 Diabetes Mellitus	1
2	Completed	Treatment	Acute Lymphoblastic Leukaemias (ALL) / Leukemia, Myelogenous, Chronic / Leukemia, Myeloid, Acute / Myelodysplasia / Non-Hodgkin's Lymphoma (NHL)	1
2	Completed	Treatment	Diabetes	1
2	Completed	Treatment	Diabetes Mellitus (DM)	1
2	Completed	Treatment	Diabetes Mellitus (DM) / Gastroparesis	1
2	Completed	Treatment	Diabetes Mellitus, Non Insulin Dependent / Type 2 Diabetes Mellitus	1
2	Completed	Treatment	Diabetes Mellitus, Non-Insulin-Dependent	1
2	Completed	Treatment	Diabetes, Diabetes Mellitus Type 1	1
2	Completed	Treatment	Glucose tolerance impaired	1
2	Completed	Treatment	HIV-1 Infections	1
2	Completed	Treatment	Non- Alcoholic Fatty Liver Disease / Non-Alcoholic Fatty Liver Disease (NAFLD)	1
2	Completed	Treatment	Psoriasis	1
2	Completed	Treatment	Psoriasis / Type 2 Diabetes Mellitus	1
2	Completed	Treatment	Type 2 Diabetes Mellitus	22
2	Not Yet Recruiting	Treatment	Type 2 Diabetes Mellitus	1
2	Recruiting	Prevention	Posttransplant Diabetes Mellitus	1
2	Recruiting	Treatment	Atherosclerosis / Inflammatory Reaction	1
2	Terminated	Basic Science	Type 2 Diabetes Mellitus	1
2	Terminated	Treatment	Cystic Fibrosis (CF)	1
2	Terminated	Treatment	Diabetes, Autoimmune / Diabetes, Diabetes Mellitus Type 1	1
2	Unknown Status	Health Services Research	Glucose Homeostasis	1
2	Unknown Status	Treatment	Diabetes, Diabetes Mellitus Type 1	1
2	Unknown Status	Treatment	Impaired Glucose Tolerance (IGT)	1
2	Unknown Status	Treatment	Pre-Diabetic	1
2	Withdrawn	Treatment	Type 2 Diabetes Mellitus	1
2, 3	Completed	Not Available	Diabetes / Insulin Resistance	1
2, 3	Completed	Basic Science	Hyperlipidemias	1
2, 3	Completed	Treatment	Diabetes	1
2, 3	Completed	Treatment	Type 2 Diabetes Mellitus	2
2, 3	Not Yet Recruiting	Treatment	Diabetes Mellitus (DM) / Gastroduodenal Ulcers / Iron Metabolism Disorders / Optic Atrophy / Platelets Dysfunction / Sensorineural Hearing Loss	1
2, 3	Unknown Status	Treatment	Acute Myocardial Infarction (AMI)	1
3	Active Not Recruiting	Treatment	Diabetes / Type 2 Diabetes Mellitus	2
3	Active Not Recruiting	Treatment	Type 2 Diabetes Mellitus	5
3	Completed	Basic Science	Type 2 Diabetes Mellitus	1
3	Completed	Treatment	Cardiovascular Disease (CVD) / Inflammatory Reaction / Macrophage Infiltration	1
3	Completed	Treatment	Chronic Renal Insufficiency / Type 2 Diabetes Mellitus	1
3	Completed	Treatment	Diabetes Mellitus (DM) / Postprandial Lipaemia	1
3	Completed	Treatment	Diabetes Mellitus, Non-Insulin-Dependent	3
3	Completed	Treatment	Diabetes Mellitus, Non-Insulin-Dependent / Type 2 Diabetes Mellitus, Non Insulin Dependent	1
3	Completed	Treatment	Diabetes / Type 2 Diabetes Mellitus	5
3	Completed	Treatment	End-Stage Kidney Disease / Type 2 Diabetes Mellitus	1
3	Completed	Treatment	Hyperlipidemias / Type 2 Diabetes Mellitus	1
3	Completed	Treatment	Impaired Renal Function / Type 2 Diabetes Mellitus	1
3	Completed	Treatment	Renal Insufficiency,Chronic / Type 2 Diabetes Mellitus	1
3	Completed	Treatment	Type 2 Diabetes Mellitus	71
3	Not Yet Recruiting	Treatment	Diabetes / Type 2 Diabetes Mellitus	1
3	Not Yet Recruiting	Treatment	Type 2 Diabetes Mellitus	2
3	Recruiting	Prevention	Healthy Volunteers	1
3	Recruiting	Treatment	Cardiovascular Disease (CVD) / Type 2 Diabetes Mellitus	1
3	Recruiting	Treatment	Comparative Effectiveness of Glycemia-lowering Medications / Type 2 Diabetes Mellitus	1
3	Recruiting	Treatment	Diabetes Mellitus (DM) / Type 2 Diabetes Mellitus	1
3	Recruiting	Treatment	Type 2 Diabetes Mellitus	3
3	Terminated	Prevention	Cystic Fibrosis (CF) / Pre-Diabetic	1
3	Terminated	Treatment	Glycemic Control	1
3	Terminated	Treatment	Impaired Renal Function / Type 2 Diabetes Mellitus	1
3	Terminated	Treatment	Type 2 Diabetes Mellitus	5
3	Unknown Status	Treatment	Islet Transplantation	1
3	Unknown Status	Treatment	Type 2 Diabetes Mellitus	1
3	Withdrawn	Prevention	Type 2 Diabetes Mellitus	1
3	Withdrawn	Treatment	Diabetic Foot	1
3	Withdrawn	Treatment	Type 2 Diabetes Mellitus	2
4	Active Not Recruiting	Basic Science	Healthy Volunteers	1
4	Active Not Recruiting	Basic Science	Type 2 Diabetes Mellitus	2
4	Completed	Not Available	Healthy Volunteers	1
4	Completed	Basic Science	Atherosclerosis / Diabetes	1
4	Completed	Basic Science	Healthy Volunteers / Type 2 Diabetes Mellitus	1
4	Completed	Basic Science	Hypertensive / Metabolic Syndromes	1
4	Completed	Basic Science	Type 2 Diabetes Mellitus	1
4	Completed	Other	BMI >30 kg/m2	1
4	Completed	Prevention	Coronary Artery Disease	1
4	Completed	Prevention	Polycystic Ovarian Syndrome	1
4	Completed	Treatment	Body Weights / Polycystic Ovaries Syndrome	1
4	Completed	Treatment	Coronary Artery Disease / Newly Diagnosed Type 2 Diabetes	1
4	Completed	Treatment	DIABETES Mellitus Type 2 Not Well Controlled	1
4	Completed	Treatment	Diabetes	3
4	Completed	Treatment	Diabetes Ketoacidosis / Hyperglycemias / Ketosis Prone Diabetes	1
4	Completed	Treatment	Diabetes Mellitus (DM)	2
4	Completed	Treatment	Diabetes Mellitus (DM) / Impaired Glucose Tolerance (IGT) / Myocardial Infarction (MI) / Unstable Angina Pectoris	1
4	Completed	Treatment	Diabetes, Diabetes Mellitus Type 1	3
4	Completed	Treatment	Diabetes / Pancreatitis	1
4	Completed	Treatment	Diabetes / Type 2 Diabetes Mellitus	3
4	Completed	Treatment	Glucose tolerance impaired	1
4	Completed	Treatment	Hospitalization / Hyperglycemias / Type 2 Diabetes Mellitus	1
4	Completed	Treatment	Pre-Diabetic	1
4	Completed	Treatment	Reactive Hypoglycemia	1
4	Completed	Treatment	Type 2 Diabetes Mellitus	25
4	Enrolling by Invitation	Treatment	BMI >30 kg/m2 / General Surgery / Hypoglycemia	1
4	Enrolling by Invitation	Treatment	Type 2 Diabetes Mellitus	1
4	Not Yet Recruiting	Treatment	Coronary Heart Disease (CHD) / Diabetes Mellitus (DM)	1
4	Recruiting	Not Available	Polycystic Ovaries Syndrome	1
4	Recruiting	Not Available	Type 2 Diabetes Mellitus	1
4	Recruiting	Basic Science	BMI >30 kg/m2 / Pre-Diabetic	1
4	Recruiting	Basic Science	Type 2 Diabetes Mellitus	1
4	Recruiting	Health Services Research	Type 2 Diabetes Mellitus	1
4	Recruiting	Prevention	Hyperglycemias	2
4	Recruiting	Supportive Care	Acromegaly / Cushing's Disease	1
4	Recruiting	Treatment	Acute Coronary Syndromes (ACS) / Type 2 Diabetes Mellitus	1
4	Recruiting	Treatment	Atherosclerosis / Type 2 Diabetes Mellitus	1
4	Recruiting	Treatment	Cholesterol, LDL / Coronary Heart Disease (CHD) / Diabetes Mellitus (DM) / Dipeptidyl-Peptidase 4 Inhibitors / Glycosylated Hemoglobin	1
4	Recruiting	Treatment	Diabetes Mellitus (DM)	1
4	Recruiting	Treatment	Disorder of Glucose Regulation	1
4	Recruiting	Treatment	Heart Failure, Systolic / Type 2 Diabetes Mellitus	1
4	Recruiting	Treatment	Heart Failure, Unspecified / Type 2 Diabetes Mellitus	1
4	Recruiting	Treatment	Neoplasms, Adipose Tissue	1
4	Recruiting	Treatment	Non-Alcoholic Fatty Liver Disease (NAFLD)	1
4	Recruiting	Treatment	Short Bowel Syndrome (SBS)	1
4	Recruiting	Treatment	Type 2 Diabetes Mellitus	9
4	Recruiting	Treatment	Type II Diabetes in Subjects BMI 27 to 32 / Type II Diabetes in the Not so Obese	1
4	Terminated	Treatment	Diabetes / Hypoglycemia	1
4	Terminated	Treatment	Hyperglycemias / Type 2 Diabetes Mellitus	1
4	Terminated	Treatment	Microalbuminuria / Microalbuminuria in Type Two Diabetes / Type 2 Diabetes Mellitus	1
4	Terminated	Treatment	Type 2 Diabetes Mellitus	5
4	Unknown Status	Not Available	Type 2 Diabetes Mellitus	1
4	Unknown Status	Basic Science	Type 2 Diabetes Mellitus	1
4	Unknown Status	Prevention	Diabetes / Transplant, Kidney	1
4	Unknown Status	Treatment	Chronic Liver Diseases (CLD) / Type 2 Diabetes Mellitus	1
4	Unknown Status	Treatment	Diabetes, Diabetes Mellitus Type 1	1
4	Unknown Status	Treatment	Type 2 Diabetes Mellitus	4
4	Withdrawn	Treatment	Non-Alcoholic Fatty Liver Disease (NAFLD) / Type 2 Diabetes Mellitus	1
Not Available	Active Not Recruiting	Treatment	Diabetes	1
Not Available	Completed	Not Available	Diabetes, Diabetes Mellitus Type 1 / Hypoglycemia	1
Not Available	Completed	Not Available	Diabetes / Type 2 Diabetes Mellitus	1
Not Available	Completed	Not Available	Type 2 Diabetes Mellitus	9
Not Available	Completed	Basic Science	Obesity, Severe	1
Not Available	Completed	Prevention	BMI >30 kg/m2 / Type 2 Diabetes Mellitus	1
Not Available	Completed	Prevention	Beta-cell Function / Diabetes Mellitus (DM) / Glucocorticoid-induced Diabetes / Steroid Diabetes	1
Not Available	Completed	Supportive Care	Diabetes, Diabetes Mellitus Type 1	1
Not Available	Completed	Treatment	BMI >30 kg/m2	1
Not Available	Completed	Treatment	Diabetes Mellitus, Non-Insulin-Dependent	1
Not Available	Completed	Treatment	Hypertensive / Type 2 Diabetes Mellitus	1
Not Available	Completed	Treatment	Pre-Diabetic / Type 2 Diabetes Mellitus	1
Not Available	Completed	Treatment	Type 2 Diabetes Mellitus	6
Not Available	Completed	Treatment	Type 2 Diabetes Mellitus / Type2 Diabetes Mellitus	1
Not Available	Not Yet Recruiting	Not Available	Type 2 Diabetes Mellitus	3
Not Available	Not Yet Recruiting	Treatment	Type 2 Diabetes Mellitus	1
Not Available	Recruiting	Not Available	Cardiovascular Disease (CVD) / Type 2 Diabetes Mellitus	1
Not Available	Recruiting	Not Available	Cystic Fibrosis (CF) / Pancreatic Insufficiency	1
Not Available	Recruiting	Basic Science	Physiology	1
Not Available	Recruiting	Other	Type 2 Diabetes Mellitus	1
Not Available	Recruiting	Treatment	Hypertensive / Type 2 Diabetes Mellitus	1
Not Available	Recruiting	Treatment	Type 2 Diabetes Mellitus	1
Not Available	Terminated	Not Available	Type 2 Diabetes Mellitus	1
Not Available	Terminated	Prevention	Prediabetic State	1
Not Available	Terminated	Treatment	Nonalcoholic Steatohepatitis / Type 2 Diabetes Mellitus	1
Not Available	Unknown Status	Not Available	Arterial Stiffness / Diabetes Mellitus (DM)	1
Not Available	Unknown Status	Prevention	Incretinomimetics / Pancreas / Type 2 Diabetes Mellitus	1
Not Available	Unknown Status	Treatment	Diabetes Type I	1
Not Available	Unknown Status	Treatment	Transplant, Kidney / Type 2 Diabetes Mellitus	1
Not Available	Unknown Status	Treatment	Type 2 Diabetes Mellitus	3

Pharmacoeconomics

Manufacturers

Not Available

Packagers

AQ Pharmaceuticals Inc.
A-S Medication Solutions LLC
Lake Erie Medical and Surgical Supply
Merck & Co.
Murfreesboro Pharmaceutical Nursing Supply
Physicians Total Care Inc.
Resource Optimization and Innovation LLC

Dosage forms

Form	Route	Strength
Tablet	Oral
Tablet, film coated	Oral
Tablet, extended release	Oral
Tablet, film coated, extended release	Oral
Tablet	Oral	100 mg
Tablet	Oral	25 mg
Tablet	Oral	50 mg
Tablet, film coated	Oral	100 mg
Tablet, film coated	Oral	100 mg/1
Tablet, film coated	Oral	25 mg
Tablet, film coated	Oral	25 mg/1
Tablet, film coated	Oral	50 mg/1
Tablet, film coated	Oral	50 mg

Prices

Unit description	Cost	Unit
Januvia 90 25 mg tablet Bottle	686.36USD	bottle
Januvia 30 100 mg tablet Bottle	228.81USD	bottle
Januvia 50 mg tablet	7.48USD	tablet
Januvia 100 mg tablet	7.33USD	tablet
Januvia 25 mg tablet	7.33USD	tablet

DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.

Patents

Patent Number	Pediatric Extension	Approved	Expires (estimated)
CA2450740	No	2006-02-14	2022-07-05	Canada
CA2536251	No	2009-08-04	2024-08-27	Canada
US6303661	No	1997-04-24	2017-04-24	US
US6340475	No	1996-09-19	2016-09-19	US
US6635280	No	1996-09-19	2016-09-19	US
US6699871	No	2002-07-26	2022-07-26	US
US6890898	No	1999-02-02	2019-02-02	US
US7078381	No	1999-02-02	2019-02-02	US
US7125873	No	2002-07-26	2022-07-26	US
US7326708	No	2006-04-11	2026-04-11	US
US7459428	No	1999-02-02	2019-02-02	US
US8168637	No	2002-06-26	2022-06-26	US
US8414921	No	2008-07-21	2028-07-21	US

Properties

State

Solid

Experimental Properties

Property	Value	Source
logP	1.5	Not Available

Predicted Properties

Property	Value	Source
Water Solubility	0.034 mg/mL	ALOGPS
logP	1.95	ALOGPS
logP	1.26	ChemAxon
logS	-4.1	ALOGPS
pKa (Strongest Basic)	8.78	ChemAxon
Physiological Charge	1	ChemAxon
Hydrogen Acceptor Count	4	ChemAxon
Hydrogen Donor Count	1	ChemAxon
Polar Surface Area	77.04 Å²	ChemAxon
Rotatable Bond Count	5	ChemAxon
Refractivity	87.49 m³·mol^-1	ChemAxon
Polarizability	32.66 Å³	ChemAxon
Number of Rings	3	ChemAxon
Bioavailability	1	ChemAxon
Rule of Five	Yes	ChemAxon
Ghose Filter	Yes	ChemAxon
Veber's Rule	Yes	ChemAxon
MDDR-like Rule	Yes	ChemAxon

Predicted ADMET features

Property	Value	Probability
Human Intestinal Absorption	+	1.0
Blood Brain Barrier	+	0.9438
Caco-2 permeable	-	0.6415
P-glycoprotein substrate	Substrate	0.6509
P-glycoprotein inhibitor I	Inhibitor	0.7141
P-glycoprotein inhibitor II	Inhibitor	0.5248
Renal organic cation transporter	Inhibitor	0.592
CYP450 2C9 substrate	Non-substrate	0.9277
CYP450 2D6 substrate	Non-substrate	0.7228
CYP450 3A4 substrate	Substrate	0.6412
CYP450 1A2 substrate	Non-inhibitor	0.7178
CYP450 2C9 inhibitor	Inhibitor	0.6111
CYP450 2D6 inhibitor	Non-inhibitor	0.538
CYP450 2C19 inhibitor	Inhibitor	0.7048
CYP450 3A4 inhibitor	Inhibitor	0.5358
CYP450 inhibitory promiscuity	High CYP Inhibitory Promiscuity	0.8336
Ames test	Non AMES toxic	0.5487
Carcinogenicity	Non-carcinogens	0.7973
Biodegradation	Not ready biodegradable	1.0
Rat acute toxicity	2.8093 LD50, mol/kg	Not applicable
hERG inhibition (predictor I)	Weak inhibitor	0.7076
hERG inhibition (predictor II)	Inhibitor	0.6936

ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )

Spectra

Mass Spec (NIST)

Not Available

Spectra

Spectrum Type	Description	Splash Key
LC-MS/MS	LC-MS/MS Spectrum - LC-ESI-QTOF , positive	splash10-0a4i-0000900000-ce9211ae5927c697618c	View in MoNA
LC-MS/MS	LC-MS/MS Spectrum - LC-ESI-QTOF , positive	splash10-052r-0690500000-c28779e719a0e517d106	View in MoNA
LC-MS/MS	LC-MS/MS Spectrum - LC-ESI-QTOF , positive	splash10-0076-0930000000-1337dd7fb10ab92722b5	View in MoNA
LC-MS/MS	LC-MS/MS Spectrum - LC-ESI-QTOF , positive	splash10-00dl-0900000000-91485eb0052ad2f3637a	View in MoNA
LC-MS/MS	LC-MS/MS Spectrum - LC-ESI-QTOF , positive	splash10-00di-0900000000-7d92431093315efaed86	View in MoNA
LC-MS/MS	LC-MS/MS Spectrum - LC-ESI-ITFT , positive	splash10-000i-0390000000-c8853d370b51f01b194b	View in MoNA
LC-MS/MS	LC-MS/MS Spectrum - LC-ESI-ITFT , positive	splash10-0a4i-0000900000-2895dd4a879799635ae6	View in MoNA
LC-MS/MS	LC-MS/MS Spectrum - LC-ESI-ITFT , positive	splash10-007c-0970100000-17431cd80097dff5c35f	View in MoNA
LC-MS/MS	LC-MS/MS Spectrum - LC-ESI-ITFT , positive	splash10-00dl-0910000000-29041ebd42cb7f6026df	View in MoNA
LC-MS/MS	LC-MS/MS Spectrum - LC-ESI-ITFT , positive	splash10-00di-0900000000-dc60c3b1e5f0ba0e5e23	View in MoNA
LC-MS/MS	LC-MS/MS Spectrum - LC-ESI-ITFT , positive	splash10-0umi-0900000000-b1e1f886377c8d9b2a5d	View in MoNA
LC-MS/MS	LC-MS/MS Spectrum - LC-ESI-ITFT , positive	splash10-004i-0900000000-d9e2b332d0ff3c6e283b	View in MoNA
LC-MS/MS	LC-MS/MS Spectrum - LC-ESI-ITFT , positive	splash10-0a4i-0000900000-3403c0e74f19a7d0832a	View in MoNA
LC-MS/MS	LC-MS/MS Spectrum - LC-ESI-ITFT , positive	splash10-007c-0970000000-6aa1fc14d171d0102a2c	View in MoNA
LC-MS/MS	LC-MS/MS Spectrum - LC-ESI-ITFT , positive	splash10-00dl-0910000000-62ba59074d19e0d89306	View in MoNA
LC-MS/MS	LC-MS/MS Spectrum - LC-ESI-ITFT , positive	splash10-00di-0900000000-91600010aa7e80c0e67c	View in MoNA
LC-MS/MS	LC-MS/MS Spectrum - LC-ESI-ITFT , positive	splash10-0fmi-0900000000-d38f8b74df088a3b8232	View in MoNA
LC-MS/MS	LC-MS/MS Spectrum - LC-ESI-ITFT , positive	splash10-004i-0900000000-08cf9f4ac284f2cd9057	View in MoNA
LC-MS/MS	LC-MS/MS Spectrum - LC-ESI-ITFT , positive	splash10-000i-0390000000-b6e5cd73f4ff7abd2747	View in MoNA
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 10V, Positive	Not Available
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 20V, Positive	Not Available
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 40V, Positive	Not Available
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 10V, Negative	Not Available
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 20V, Negative	Not Available
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 40V, Negative	Not Available

Taxonomy

Description

This compound belongs to the class of organic compounds known as beta amino acids and derivatives. These are amino acids having a (-NH2) group attached to the beta carbon atom.

Kingdom

Organic compounds

Super Class

Organic acids and derivatives

Class

Carboxylic acids and derivatives

Sub Class

Amino acids, peptides, and analogues

Direct Parent

Beta amino acids and derivatives

Alternative Parents

Amphetamines and derivatives / Triazolopyrazines / Aralkylamines / Fluorobenzenes / Pyrazines / Aryl fluorides / Triazoles / Tertiary carboxylic acid amides / Heteroaromatic compounds / Azacyclic compounds

Substituents

Beta amino acid or derivatives / Amphetamine or derivatives / Triazolopyrazine / Fluorobenzene / Halobenzene / Aralkylamine / Aryl fluoride / Aryl halide / Monocyclic benzene moiety / Pyrazine

Molecular Framework

Aromatic heteropolycyclic compounds

External Descriptors

trifluorobenzene, triazolopyrazine (CHEBI:40237 )

Targets

Details

1. Dipeptidyl peptidase 4

Kind: Protein
Organism: Human
Pharmacological action: yes
Actions: inhibitor

General Function:: Virus receptor activity
Specific Function:: Cell surface glycoprotein receptor involved in the costimulatory signal essential for T-cell receptor (TCR)-mediated T-cell activation. Acts as a positive regulator of T-cell coactivation, by binding at least ADA, CAV1, IGF2R, and PTPRC. Its binding to CAV1 and CARD11 induces T-cell proliferation and NF-kappa-B activation in a T-cell receptor/CD3-dependent manner. Its interaction with ADA also ...
Gene Name:: DPP4
Uniprot ID:: P27487
Molecular Weight:: 88277.935 Da

References

Herman GA, Stevens C, Van Dyck K, Bergman A, Yi B, De Smet M, Snyder K, Hilliard D, Tanen M, Tanaka W, Wang AQ, Zeng W, Musson D, Winchell G, Davies MJ, Ramael S, Gottesdiener KM, Wagner JA: Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: results from two randomized, double-blind, placebo-controlled studies with single oral doses. Clin Pharmacol Ther. 2005 Dec;78(6):675-88. [PubMed:16338283 ]
Bergman AJ, Stevens C, Zhou Y, Yi B, Laethem M, De Smet M, Snyder K, Hilliard D, Tanaka W, Zeng W, Tanen M, Wang AQ, Chen L, Winchell G, Davies MJ, Ramael S, Wagner JA, Herman GA: Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers. Clin Ther. 2006 Jan;28(1):55-72. [PubMed:16490580 ]
Gallwitz B: Therapies for the treatment of type 2 diabetes mellitus based on incretin action. Minerva Endocrinol. 2006 Jun;31(2):133-47. [PubMed:16682937 ]
Herman GA, Bergman A, Liu F, Stevens C, Wang AQ, Zeng W, Chen L, Snyder K, Hilliard D, Tanen M, Tanaka W, Meehan AG, Lasseter K, Dilzer S, Blum R, Wagner JA: Pharmacokinetics and pharmacodynamic effects of the oral DPP-4 inhibitor sitagliptin in middle-aged obese subjects. J Clin Pharmacol. 2006 Aug;46(8):876-86. [PubMed:16855072 ]
Miller S, St Onge EL: Sitagliptin: a dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. Ann Pharmacother. 2006 Jul-Aug;40(7-8):1336-43. [PubMed:16868220 ]
Karasik A, Aschner P, Katzeff H, Davies MJ, Stein PP: Sitagliptin, a DPP-4 inhibitor for the treatment of patients with type 2 diabetes: a review of recent clinical trials. Curr Med Res Opin. 2008 Feb;24(2):489-96. doi: 10.1185/030079908X261069 . [PubMed:18182122 ]
Pratley RE, Salsali A: Inhibition of DPP-4: a new therapeutic approach for the treatment of type 2 diabetes. Curr Med Res Opin. 2007 Apr;23(4):919-31. [PubMed:17407649 ]
Lyseng-Williamson KA: Sitagliptin. Drugs. 2007;67(4):587-97. [PubMed:17352516 ]
Hermansen K, Kipnes M, Luo E, Fanurik D, Khatami H, Stein P: Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin. Diabetes Obes Metab. 2007 Sep;9(5):733-45. Epub 2007 Jun 26. [PubMed:17593236 ]
Gallwitz B: Sitagliptin: Profile of a novel DPP-4 inhibitor for the treatment of type 2 diabetes. Drugs Today (Barc). 2007 Jan;43(1):13-25. [PubMed:17315049 ]
Richter B, Bandeira-Echtler E, Bergerhoff K, Lerch C: Emerging role of dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes. Vasc Health Risk Manag. 2008;4(4):753-68. [PubMed:19065993 ]
Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]

Enzymes

Details

1. Cytochrome P450 3A4

Kind: Protein
Organism: Human
Pharmacological action: unknown
Actions: substrate

General Function:: Vitamin d3 25-hydroxylase activity
Specific Function:: Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:: CYP3A4
Uniprot ID:: P08684
Molecular Weight:: 57342.67 Da

References

Scheen AJ: Pharmacokinetics of dipeptidylpeptidase-4 inhibitors. Diabetes Obes Metab. 2010 Aug;12(8):648-58. doi: 10.1111/j.1463-1326.2010.01212.x. [PubMed:20590741 ]

Details

2. Cytochrome P450 2C8

Kind: Protein
Organism: Human
Pharmacological action: unknown
Actions: substrate

General Function:: Steroid hydroxylase activity
Specific Function:: Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. In the epoxidation of arachidonic acid it generates only 14,15- and 11,12-cis-epoxyeicosatrienoic acids. It is the principal enzyme...
Gene Name:: CYP2C8
Uniprot ID:: P10632
Molecular Weight:: 55824.275 Da

References

Scheen AJ: Pharmacokinetics of dipeptidylpeptidase-4 inhibitors. Diabetes Obes Metab. 2010 Aug;12(8):648-58. doi: 10.1111/j.1463-1326.2010.01212.x. [PubMed:20590741 ]

Transporters

Details

1. Multidrug resistance protein 1

Kind: Protein
Organism: Human
Pharmacological action: unknown
Actions: substrate

General Function:: Xenobiotic-transporting atpase activity
Specific Function:: Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:: ABCB1
Uniprot ID:: P08183
Molecular Weight:: 141477.255 Da

References

Scheen AJ: Pharmacokinetics of dipeptidylpeptidase-4 inhibitors. Diabetes Obes Metab. 2010 Aug;12(8):648-58. doi: 10.1111/j.1463-1326.2010.01212.x. [PubMed:20590741 ]

Drug created on May 16, 2007 11:36 / Updated on July 11, 2017 02:01

Get DrugBank to go!

Structure for DB01261 (Sitagliptin)

Targets

References

Enzymes

References

References

Transporters

References